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The development of the postnatal mammary gland is tightly controlled by peptide 
hormones and cytokines. The signaling of these extracellular ligands through their 
corresponding receptors rely on Janus Kinases (JAKs) that activate downstream Signal 
Transducers and Activators of Transcription (STATs). The JAK/STAT signaling pathway 
is crucial for processes such as growth, proliferation, and cell survival of the epithelial 
tissue, but also for the breakdown and remodeling of the mammary gland via IL-6 class 
inflammatory cytokines (e.g. LIF and OSM). JAK1 and JAK2, which are expressed in the 
mammary gland, are thought to have redundant functions. However, our previous 
studies demonstrated that JAK2 is exclusively required for the activation of STAT5 as 
well as the growth and functional differentiation of the gland. In contrast to the general 
paradigm, JAK2 might be dispensable for the activation of STAT3 in response to IL-6 
class inflammatory cytokines. Utilizing the recently generated JAK1 conditional knockout 
mouse model, we demonstrate that Janus kinase 1 is the essential kinase responsible 
for mediating inflammatory cytokine signaling in the mammary gland, specifically during 
postlactational remodeling events where the absence of JAK1 delayed involution. 
Ablation of JAK1 in the mammary epithelium of mice dramatically prevented the 
activation of STAT3 and uncoupled signaling of IL-6 class ligands such as OSM and LIF 
from their downstream effectors. Completing the profile of STATs, JAK1 was also found 
to play a non-redundant role in the activation of STAT1 and STAT6 but not STAT5.  
 Building on the evidence that JAK1 contributes to the activation of STAT3 in non-
transformed mammary epithelial cells, we next tested if JAK1 maintained discretion in 
the activation of STAT3 in neoplastic tissue. A notorious transcription factor, active 
STAT3 has been tightly linked to aggressive disease, promoting a metastatic phenotype 
in breast cancers, notably, a subset of which that overexpress the human epidermal 
growth factor ErbB2/Her2. Using the mammary-specific deletion of JAK1 in the context 
of ErbB2 oncogenesis, we found that while JAK1 does not affect the tumor onset, it 
dramatically decreases STAT3 activity and occurrence of metastasis. Interestingly, we 
found that JAK1 is also required for the tumor-initiating cell population of established 
disease. 
 Collectively, the results of these studies describe the novel role of Janus kinase 1 
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1.1.  Structure and Function of Janus Kinases and STATs 
 
1.1.1.  Activation of JAKs and STATs 
Mammalian systems have an abundance of growth factors, peptide hormones, 
and cytokines, and rely on these ligands to initiate and promote physiological changes 
such as growth, proliferation, or conversely, apoptosis. Signaling of these extracellular 
ligands through their corresponding receptors rely on Janus Kinases (JAKs) to activate 
downstream Signal Transducers and Activators of Transcription (STATs). Upon ligand 
binding, the corresponding receptor will recruit membrane receptor-associated Janus 
kinases which then autophosphorylate at tyrosine residues and become activated. 
Activated JAKs will provide phosphorylation on tyrosine sites of their associated 
receptor. These activated tyrosine sites provide a docking site for intracellular signal 
transducers and activators of transcription (STATs). Following recruitment to the 
receptor, STATs will be activated by JAKs through phosphorylation at tyrosine residues. 
On the STAT protein, the modification promotes binding sites of Src Homology 2 
domains of subsequent STAT proteins. Binding produces a stable homo- or 
heterodimerization of the STATs, allowing the transcription factors to undergo 
translocation to the nucleus, where they bind DNA and affect transcription activity. 
While there are four members of the JAK family are JAK1, JAK2, JAK3, and TYK2, 
each are able to phosphorylate select STATs of the seven-member family (STAT1, 
STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6). The crucial determinate to 
exploring which JAK that will activate a STAT protein is likely context-dependent, first 











Figure 1.1. The JAK/STAT signaling pathway. The activation of the JAK/STAT signal 
transduction pathway begins with 1) the unbound receptor that binds with its 
corresponding ligand. 2) The binding induces a conformation change, recruits a Janus 
kinase that will auto-phosphorylate and create docking sites for the unbound STAT 
proteins. 3) The phosphorylated, and now active STATs dimerize and translocate to the 
nucleus where they recognize and bind GAS consensus sequences, initiating 
transcription of target genes. Among the regulators within the pathway are suppressors 
of cytokine signaling (SOCS) which inhibit active JAKs, protein tyrosine phosphatases 
(PTPs) that function to dephosphorylate JAKs as well as STATs, and protein inhibitors of 
activated STATs (PIAS), which can inhibit the translocation of STATs to the nucleus. 
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1.1.2  Structure and function of Janus kinases 
 
Janus kinases are comprised of seven domains and are described by homology 
between the Janus kinases, referred to as Jak homology (JH) domains. Their hallmark 
characteristics are the tandem kinase domains, discovered in 1989 by Wilks et al., 
during the initial cloning [1, 2]. When it was first discovered, the kinase was named JAK, 
for ‘Just Another Kinase’, until it was found to have the two kinase domains, with one 
lacking enzymatic activity. It was aptly renamed ‘Janus kinase’, modeling the Roman 
two-faced god of the gates and doorways [3-6]. The first domain at the C-terminus is 
JH1 and is the catalytically active site. The second domain, JH2 is the catalytically 
inactive, pseudokinase domain, which could serve as a negative regulator for the 
catalytic domain, substrate localization, or supply a structural role in supporting the 
catalytic JH1 domain [7, 8]. The family also shares five other homology domains, 
directed from C to N-terminus.  JH3 holds the src-homolgy 2 (SH2) domain, and little is 
known about its function. The remaining region, JH4-7, contains the four-point-one, 
ezrin, radixin, moesin (FERM) domain. The FERM domain is thought to coordinate with 
the cytoplasmic portion of the cell receptor, as a study explored the truncated amino-
terminus of JAK2 and observed the kinase lost its ability to associate with the growth 
hormone receptor [9] (Fig. 1.2. Top). The resulting protein ranges from 120-140 kDa in 
size. 
 
1.1.3 Developmental Analysis: Knockout models of the Janus kinases 
 To understand the biological implications in development of the Janus kinase 
family, knockout models have been generated. Conventional deletion refers to the target 
gene being inactivated in all cells of the organism. Conditional models are an elegant 
tool used to not only bypass embryonic lethality that is commonly seen in conventional 
models, but also an effective way to excise genes in a temporal and spatial manner. 
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 Knockout models have been generated to address the role of several Janus 
kinases in development. Janus kinase 2 was found to have the most severe phenotype, 
embryos died in utero near embryonic day 12.5, due to inadequate erythropoiesis [10, 
11].  To circumvent the lethality during gestation, a conditional Jak2 mouse model was 
generated, and in concordance with observations made from the germ line knockout, 
JAK2 has been shown to mediate the signaling of growth hormone (GH), erythropoietin, 
as well as prolactin [12-15]. Additionally, conditional knockout models describe integral 
function of JAK2 in mediating signaling in gonadotropin-releasing neurons [16]. The 
commonality of the ligands is that they are associated with single-chain receptors.  
 Janus kinase 3 is mainly restricted to the hematopoietic compartment, 
associating with the common gamma chain of interleukin (IL) receptor-2, IL-4, IL-7, IL-9, 
and IL-15 [17, 18]. Deletion of Jak3 was not lethal, and mice were viable and fertile, 
although when Jak3-deficeint mice were analyzed, the role of JAK3 and gamma chain 
receptors was confirmed, as mutant mice were found to have a thymocyte phenotype as 
ablation of Jak3 resulted in severe lymphopenia, a decrease of the B and T cells [19]. 
 Janus kinase 1 knockout mice have been generated, and mutant mice lacking 
the tyrosine kinase die shortly after birth due to neurologic defects and its effects had not 
been addressed in adult tissue. In the 1998 study, analysis of collected cardiomyocytes, 
macrophages, and embryonic fibroblasts demonstrate that Jak1 may be responsible for 
cytokines such as IL-2, IL-6, LIF, and IFN [20]. In order to address the response of cells 
from these ligands in postnatal development, a conditional knockout would need to be 
generated. 
  The fourth member of the JAK family, and first to be identified during a search 
for tyrosine kinases, is Tyrosine kinase 2 (TYK2) [21, 22]. The knockout revealed a 
partial dependency of this JAK family member for the response of IFN α/β and gamma, 
as well as IL-12. The phenotypic role was described by Karaghiosoff et al. to have a 
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predominate effect in the immune response, specifically in select antiviral mechanisms 
[23]. In contrast to the other JAK family members, TYK2 had redundant role in mediating 
receptor complex activation, although it had a crucial role in innate and adaptive immune 
responses.  
  
1.1.4 Structure of STATs 
 The STAT proteins carry two roles in the cascade of signaling events, the first 
being signal transduction, carrying the signal after becoming activated by a Janus kinase 
and the second is activating transcription. STATs perform the later by translocating to 
the nucleus as a dimer and bind to recognition sequences on the DNA, the gamma 
interferon activation sites (GAS), recognizing consensus sequences, TTCNNNNGAA. 
STATs are composed of five domains: the amino-terminus, DNA-binding, SH3-like, SH-
2, and the carboxy-terminus transactivating domain (Fig. 1.2. Lower). Both the amino-
terminus and the DNA-binding domains are highly conserved between the STAT 
members. The DNA-binding domain will interact with the DNA. The C-terminal activating 
domain is also conserved among the STAT proteins. The tyrosine in this domain, once 
phosphorylated allows for the subsequent dimerization at the SH2 domain, mediating the 
binding partners (other STAT proteins). Dimerization occurs as homo dimers between 
STATs or as heterodimers. Whether a one dimerization occurs over another is context 
and STAT-dependent, as some STATs are exclusive for only forming one or the other 
and with specific STATs. Such as, STAT1 and STAT3 can heterodimerize with one 
another, and STAT2 will only form a heterodimer with STAT1, and but will not form a 
homodimer [24].  
Serine phosphorylation has been reported in the case of STAT1 and STAT3, at S727 at 
the C-terminus (Wen 1995) Zhang 1995), and may enhance the tyrosine 





Fig. 1.2.  
 10 
Figure 1.2. Structure of the Janus kinase and STAT protein. The Janus kinase (top) 
is comprised of seven JAK homology domains (JH), regions that share similarity 
between the four family members. JH1 serves as the catalytically active kinase domain, 
followed by the JH2, psuedokinase domain. The amino-terminal FERM domain interacts 
with the cytoplasmic portion of the receptor. The STAT protein (lower) contains the 
domains necessary for protein-protein interaction, the amino-terminus domain and the 
coiled-coil domain. The DNA-binding domain recognizes consensus sequences in the 
DNA. The SH2 domain is responsible for the tyrosine phosphorylation at the receptor 
and recruitment with other STAT proteins. 
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1.1.5 Developmental Analysis: Knockout models of the STAT proteins 
STAT1 deficiency is most apparent in IFN signaling, where STAT1 null mutants 
have decreased signaling efficiency in response to type1 and II IFNs [25, 26]. These 
knockout models produced a truncated protein with no activity (Mera, et al.) or an 
elimination of STAT1 protein (Durbin et al.). STAT1 knockout mice were viable, although 
extremely susceptible to viral infections. Conditional knockout models were later 
developed in 2010 [27], and later in 2011, which targeted exons 6-10, the DNA-binding 
domain, for deletion [28]. Using the myloid-specific promoter driving Cre recombinase, 
LysM-Cre, macrophages and neutrophils were analyzed and confirmed the 
unresponsiveness of cells to IFN signaling. 
Park et al, generated the STAT2-deficient mouse and while they were viable, 
they were found to be deficient in IFN signaling and like the STAT1 knockout mice, also 
susceptible to viral infections [29]. 
A whole-body knockout of STAT3, generated by deletion of the SH2 domain and 
tyrosine residue, was reported to be embryonic lethal [30]. The 1997 by Takeda et al., 
saw degeneration of embryos as gestation day 6. Since then, tissue-specific STAT3 
knockouts in T-cell, macrophages and neutrophils, keratinocytes, and the mammary 
gland have been analyzed [31]. STAT3-deficient T cells displayed impaired proliferation 
due to an impaired response to IL-6 signaling [32]. Macrophages and neutrophils lacking 
STAT3 had decreased IL-10 production, and experienced inflammatory response 
mediated by high levels of TNF-alpha, IFN-gamma, and IL-1 [33, 34]. Skin tissue was 
analyzed for the deletion of STAT3 [35], using the Keratin5-Cre promoter and was found 
to have decrease wound healing thought to be from the deceased motility of cells during 
epidermal regeneration, such as neovascularization and response to inflammation. On a 
closer look, the in vitro studies demonstrated that while proliferation of STAT3-deficient 
epidermal cells was unaffected, a migration assay of cells compared to wild type, a 
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knockout of STAT3 severely impaired the motility of cells. The function of STAT3 was 
addressed in the mammary gland by specifically deleting the transcription factor using 
the beta-lactoglobulin (BLG) promoter driving Cre recombinase expression [36]. The 
study was the first to describe that STAT3 played a prominent role in the remodeling of 
the gland after offspring weaning, by suppressing apoptosis.  
STAT4 knockout mice had no observable phenotype and were viable, although 
studies have shown STAT4 to be highest in the spleen and testes [37]. STAT4 was 
demonstrated to mediate IL-12 signaling in both organs, specifically in the spleen STAT4 
decreased the cytolytic activity of cytotoxic T cells, and a STAT4 deficiency phenocopied 
an IL-12 knockout [38, 39].  
STAT5 has two isoforms, STAT5a and STATb and conventional models 
generated are viable [40, 41]. STAT5a knockout mice display a phenotype during 
pregnancy, where mammary gland development is impaired. STAT5b mice experienced 
growth-retardation caused by a decreased response to growth hormone (GH) [40]. 
Conditional models have addressed the role of STAT5 in the hematopoietic system and 
mammary gland development. The role of STAT5 in the context of stem cell transplants 
provided evidence that total STAT5 inhibition could promote tissue engraftment [42].   
Similar to the STAT4 model, mice deficient in STAT6 did not display a noticeable 
phenotype, but were responsible for the select ligand signaling of IL-4 [4, 43]. Mice 
lacking STAT6 lacked efficient class switching and full upregulation of B cells. 
 The use of in vivo models opens the possibility to depict the full biological 
process and roles of select genes and their proteins. Genetically engineered mouse 
models allow for describing the role of the gene in development using conventional 















Karaghiosoff et al 
Jak1 Conventional 
Embryonic lethal, 
pups died shortly 
after birth, neurologic 
defects. 






Neubauer, et al. 1998 
Parganas, et al. 1998 













Wu, et al. 2012 
Conditional, hepatocytes 
Decreased oxidative 
stress, fatty liver 
Themanns, et al. 2016 
Sos, et al. 2011 
Shi, et al. 2012 
Conditional, adipocytes Reduced lipolysis Nordstrom, et al. 2013 




Nosaka, et al. 1995 
  
Table 1.1. Knockout murine models for Janus kinase family members. Knockout 
models have been generated and phenotypes observed in whole body knockouts 
(conventional) or in a tissue specific manner (conditional). 
 14 
 





Conventional Viable, impaired IFN 
response 




Viable, impaired IFN 
response 
Wallner, et al. 2012 





Klover, et al. 2010 
Stat2 Conventional 
Viable, impaired IFN 
signaling 
Park, et al. 
Stat3 
Conventional Embryonic lethal Takeda, et al. 1997 
Conditional, T-cells 
Viable, impaired IL-6 
signaling 


























failure to lactate in 
female mice 




development. Loss of 
differentiated 
alveolar cells 














Takeda, et al. 1996 
Shimoda, et al. 1996 
Kaplan, et al. 1996 
 
Table 1.2. Knockout murine models for STAT family members. Deletion of individual 
STATs during development as a whole-body knockout (conventional) or targeted to specific 




1.2. JAKs and STATs in Mammary Gland Biology 
1.2.1 Overview of Mammary Gland Development 
The postnatal mammary gland undergoes dramatic structural changes 
throughout its development cycle. The majority of growth is seen in the nascent gland at 
the time of birth. The most prolific growth occurs throughout puberty followed by 
changes associated with pregnancy, and also addresses the remodeling of the gland 
following offspring weaning. Throughout development, the organ experiences robust 
controlled growth, cellular proliferation, as well as massive orchestrated cell death.  
This development cycle is tightly regulated by peptide hormones and cytokines, 
which elicit specific responses in the cells of the gland. Signaling of these extracellular 
ligands through their corresponding receptors rely on Janus Kinases (JAKs) to activate 
downstream Signal Transducers and Activators of Transcription (STATs). The 
JAK/STAT signaling pathway is crucial for processes such as growth, proliferation, and 
cell survival, but also for the breakdown and remodeling of the mammary gland after the 
cessation of lactation. Of the four JAK family members, (JAK1, JAK2, JAK3, and Tyk2) 
the predominately expressed Janus kinases in the mammary gland are JAK1 and JAK2. 
Currently, both kinases are thought to have redundant functions in the activation of 
selected STAT proteins. However, studies have shown that JAK2 is exclusively required 
for the activation of STAT5. JAK2/STAT5 then drives growth and functional 
differentiation of the gland in response to growth hormone and prolactin. In contrast to 
the general paradigm of redundancy between the two kinases, JAK2 may be 
dispensable during the remodeling process. The mammary gland experiences rapid 
decrease in circulating growth hormones and a rise in IL-6 class inflammatory cytokines 
(e.g. LIF and OSM) in the transition from lactation to involution. These inflammatory 
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cytokines are mediated by a Janus kinase to activate STAT3, which promotes genes 
involved in matrix remodeling and apoptosis.  
 
1.2.2 Postnatal Mammary Gland Development 
Development of the murine mammary gland begins as early as embryonic day 
10.5, when two milk lines begin to appear. Derived from the ectoderm, five symmetrical 
placodes form along each milk line at embryonic day 11.5 [44]. These placodes grow 
into the epidermis near day 14 of development to initiate the characteristic epithelial 
buds. This establishes the epithelial mesenchyme and elongation of the bud protrudes 
into the underlying fat pad, producing a small ductal tree[45]. The continued 
development occurs after birth.  
In females, the architecture of the ductal tree remains constant until 
approximately 4 weeks of age, estrogen rises during puberty and growth in the 
mammary gland is again stimulated. Proliferation occurs by ductal branching from the 
terminal end buds. The repeated estrous cycles promote branched network of ducts and 
will continue growth to fill the mammary fat pad until 10 weeks of age. At this stage the 
mature virgin mammary gland will stop growing, until prompted by a surge of growth 
hormones induced by pregnancy. 
The mammary gland is composed of many cell types. Adipose, immune cells, 
and fibroblasts are found in the stroma, while a bilayer of cells composes the alveolar 
and ductal epithelium. The bilayer consists of myoepithelial and luminal cells. 
Connecting to the basement membrane, myoepithelial cells are basally located while 
luminal cells are oriented apically. The luminal cells will function to secrete milk during 
pregnancy. 
Pregnancy induces a large, regulated proliferation in the ductal network, this time 
as tertiary structures that terminate in alveolar buds. The alveolar buds give rise to the 
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robust growth of the differentiated luminal epithelial cells to form alveoli. These cells will 
secrete milk during lactation, which will empty into the ducts to feed offspring. The 
alveolar cells are maintained throughout lactation, but when offspring are weaned the 
terminally differentiated luminal cells are no longer needed. The differentiated alveolar 
cells undergo cell death as the entire gland shifts into the next phase of development, 
known as postlactational remodeling. 
The remodeling event, also termed involution, is a dramatic example of 
orchestrated cell death. The apoptosis is necessary for the clearance of differentiated 
alveolar cells. The process of involution proceeds in two steps. The first reversible stage 
being massive programmed cell death of the differentiated alveolar cells. The second is 
irreversible, as organ undergoes architectural restructuring as the gland returns to its 
pre-pregnancy state. This stage involves breakdown of the basement membrane and 
clearance of the apoptotic cells. The once-maintained epithelium regresses and is 
replaced by adipose tissue. This reset prepares the gland for subsequent pregnancies.  
 
1.2.3 Mammary Gland Development is Orchestrated by Hormones and Locally 
Produced Cytokines 
The postnatal development of the mammary gland is regulated by growth factors, 
hormones, and locally derived cytokines. Initially, the gland responds to long-range 
endocrine hormones produced by the ovaries for the formation and elongation of ducts. 
Estrogen and progesterone mediate the ductal branching at the onset of puberty and 
during estrous cycles for the development into mature virgin glands. Peptide factors 
such as FGF and IGF have also been shown to promote ductal outgrowth and 
lobuloaveolar development[46, 47]. The growth factor amphiregulin, transcriptionally 
regulated by ERα acts through EGF receptors to also promote ductal growth [48]. The 
known pregnancy hormone, prolactin, is the prominent driver for cell proliferation and 
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survival of the secretory alveolar cells during pregnancy and the maintenance of the 
epithelium during lactation. 
When offspring are weaned, the secretory alveolar cells need to be removed, 
shifting survival signals to apoptosis. Locally derived growth factors facilitate the 
involution process. As circulating levels of prolactin decline, IL-6 class inflammatory 
cytokines rise. These inflammatory cytokines include, Oncostatin M (OSM) and leukemia 
inhibitory factor (LIF), although, IL-6 itself does not play a role in signaling during 
involution [49]. In addition, soluble factors and members of the interleukin family (IL-1α, 
IL-1β, and IL-13) [50, 51], and TGF-β3 are present [52]. The secretion of TNFα also 
signals for the recruitment of macrophages, aiding in the clearance of cell debris. 
Although they are contrasting molecular events, the signals of lactation and 
involution, together with development of the organ as a whole, share the general signal 
transduction pathway.  
 
1.2.4 Peptide hormones and locally synthesized cytokines that are essential for 
MG development utilize particular JAK/STAT pathways for intracellular signaling 
Circulating hormones and growth factors initiate their effects in the mammary 
gland by binding to their corresponding receptors, and as most cytokine receptors lack 
intrinsic kinase activity, they recruit a Janus kinase to become active. The active JAK will 
autophosphorylate and create binding site for Signal Transducers and Activators of 
Transcription (STATs). The STAT proteins will become activated by phosphorylation, 
dimerize, and translocate to the nucleus to bind to the DNA, promoting gene 
transcription. STATs may promote cell survival or cell death signals, depending on the 
upstream hormone or cytokine signal and activating Janus kinase. 
The JAK family is comprised of four members: JAK1, JAK2, JAK3, and tyrosine 
kinase 2 (TYK2). Primarily restricted to the hematopoietic system, JAK3 and TYK2 are 
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necessary for immune function, while JAK1 and 2 are more ubiquitously expressed[53]. 
In the mammary gland, JAK1 and JAK2 are recognized as being the prominent Janus 
kinases, mediating signaling of cytokines to activate downstream STATs by tyrosine 
phosphorylation. There are seven members in the STAT family: STAT1, STAT2, STAT3, 
STAT4, STAT5a, STAT5b, and STAT6. In the mammary gland, all are expressed with 
the exception of STAT2, which is found in the immune system. The activation of the 
STAT proteins varies according to the stage of mammary gland development. Prompted 
by growth and proliferation signals during pregnancy and subsequent lactation, STAT5 is 
the main driver for genes associated with cellular differentiation and survival. STAT1 has 
been demonstrated to be active in the stroma to promote ductal branching [54]. IL-4 
initiates activation of STAT6 and phenotypically, the early pregnant mammary glands of 
STAT6-deficient mice are shown to have impaired alveolar growth, although this was 
less apparent during late pregnancy [55]. The non-deleterious effects of STAT1 or 
STAT6 in the mammary gland suggest these transcription factors play subordinate roles 
in development. In contrast to cell-sustaining events, following lactation and the 
induction of mammary gland remodeling, STAT3 becomes the prominent transcription 
factor, inducing transcription of genes necessary to breakdown epithelial cells. The 
activity of the appropriate STAT protein in stages of mammary gland development is 
determined by specific growth hormones, cytokines, and a distinct Janus kinase. 
In the case of prolactin (PRL), the pregnancy-associated hormone binds to the 
prolactin receptor (PRLR). The dependence of alveolar cell growth on this pathway is 
defined by PRLR-null mice, upon pregnancy, alveolar buds failed to proliferate in 
response to PRL [56, 57].  The receptor recruits Jak2 then activating STAT5 to promote 
the AKT/PI3K pathway, upregulating genes associated with proliferation, differentiation, 
and cell survival [58]. The association of JAK2/STAT5 and mammary epithelial cell 
differentiation is well documented by in vitro and animal studies. Mice deficient in STAT5 
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specifically in the mammary epithelium failed to produce alveolar buds and undergo 
proliferation in response to prolactin stimulation[59]. A conditional deletion of Jak2 [60] in 
the mammary gland parallels the STAT5 phenotype, as ligand binding fails to activate 
the receptor and subsequent lack of STAT5 activation. Both studies phenocopy a 
prolactin receptor-deficient model, such as the mammary glands that lack any of the 
previous demonstrate loss of alveolar bud formation[56].  
 
1.2.5 Postlactational Remodeling and Inflammation 
The remodeling event is a necessary phase of mammary gland development and 
is the most dramatic series of organized cell death in the organism. The purpose is to 
terminate the functionally differentiated cells utilized during pregnancy and lactation, 
allowing the gland to reorganize into a virgin-like state before another pregnancy takes 
place. Beginning shortly after the offspring are weaned, the remodeling proceeds in two 
phases. The first phase is characterized by the apoptosis of epithelial cells no longer 
needed for milk secretion. The second phase includes cell death and also the 
breakdown and remodeling of the gland, replacing alveolar cells with adipocytes[61]. 
Inflammatory cytokines are necessary to initiate each phase. As prolactin levels 
decrease, inflammatory cytokines, leukemia inhibitory factor (LIF) and oncostatin M 
(OSM) are locally produced. Common to the family members of IL-6 class inflammatory 
cytokines, OSM receptor (OSMR) and LIF receptor (LIFR) require a GP130 subunit to be 
activated by a Janus kinase[62]. The phosphorylation by the Janus kinase allows the 
signal to be relayed from the plasma membrane to the nucleus via activated STAT 
proteins. These transcription factors will to bind to or complex with other transcription 
factors to drive transcription of genes necessary for cell death machinery and matrix 
remodeling. Given the commonality in the IL-6 signal transduction, the key convergence 
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at which a specific Janus kinase activates the receptor may represent a mechanism to 
specifically target the inflammatory pathway. 
The prominent signal transducer and activator of transcription necessary for 
mammary gland remodeling is STAT3. Conventional knockout mice identified that a 
STAT3 deficiency proved embryonic lethal [30]. Bypassing embryonic lethality, 
conditional deletion of STAT3 within the mammary gland verified STAT3 activity in 
remodeling [36]. Proceeding studies identified that loss of STAT3 and its tyrosine 
phosphorylation domain inhibited remodeling [63]. In fact, a loss of STAT3 is two-fold, as 
it extends the functionality of the gland and delays involution [64]. Previous work has 
described the integral function of LIF for the initial activation of STAT3, in the first stage 
of remodeling, as LIF-deficient mice have an absence of phosphorylated STAT3 and 
delayed mammary gland remodeling [65, 66]. Delayed remodeling is also seen in gp130-
deficeint mice [67]. This initial activation of STAT3 transcriptionally upregulates LIF 
receptor (LIFR), along with STAT3, and oncostatin m receptor (OSMR) creating a feed-
forward loop, perpetuating the activation of STAT3 by OSM, as LIF levels diminish 
leading into the second phase of remodeling[36]. Extensive tissue remodeling coupled 
with removal of the apoptotic cells in the second, irreversible phase concludes involution 





1.3. JAKs and STATs in Disease 
1.3.1 Roles of Inflammatory Cytokine Signaling in Cancer 
As one of the hallmarks of cancer, inflammation has long been associated with 
cancer progression and aggressive disease [68, 69]. Categorically separated into acute 
and chronic, inflammation attributing to disease is typically the later, as perpetual 
exposure of the inflammatory milieu may induce plasticity in epithelial cells. At the site of 
chronic inflammation, increases in immune cells, primarily macrophages, and cytokines 
are common. As chemical messengers, cytokines associated with inflammation can 
induce tissue repair and remodeling. Prevalent cytokines include tumor necrosis factor 
(TNF) and interleukin family members such as IL-6, IL-10, and IL-21. Cytokine signals 
from the environment as well as from cancer cells themselves illicit the activation primary 
cytokines and transcription factors such as nuclear factor kappaB and STAT3. Important 
for cell growth- STAT3 has been implicated in mediating the transformation of both 
human and murine cells, contributing to cancer, particularly when constitutively active 
[70]. Whereas normal cells have tight regulation on STAT3 activation, cancer cells have 
unrestricted STAT3 activity, fueling cell growth and metastatic potential. In a model of 
human prostate cells expressing a constitutively active STAT3, it was shown that STAT3 
had the capability to transform cells and modify the actin cytoskeleton thereby promoting 
migration [71]. Epithelial-Mesenchymal Transition STAT3 has also found a role in stem 
cells, as studies have linked its activity in regulating tumor-initiating cells [72-74]. 
The cytokine interleukin 6 (IL-6) has been described to have many functions 
throughout the body. Functioning from hematopoiesis to the endocrine system the cell 
types that respond to IL-6 range from macrophages to cells of the heart, liver, and ovary 
[75]. In inflammatory hepatocellular adenoma, it was demonstrated that Representative 
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of the many roles for IL-6 within the body, it’s apparent in a disease setting that the 
presence of IL-6 is not the issue but rather the persistent production of the cytokine. 
Likewise, the increased or sustained inflammatory signaling perpetuates STAT3 activity, 
such as the case in inflammatory hepatocellular adenoma and hepatocellular carcinoma 
[76, 77]. Cheng et al., demonstrated IL-6 promoted tumor growth and metastasis in a 
STAT3-dependant manner in a murine model of breast cancer [78].  
The importance of knowing the biological function of Janus kinases is crucial 
when targeting these kinases in disease. Mouse models of breast cancer clearly 
demonstrate that inhibiting JAK2 prior to disease onset results in substantial decrease of 
tumor formation[79]. This implies that JAK2 is a rational preventive therapy in human 
malignancy. However, JAK2 is dispensable not only for tumor growth in established 
disease but also for STAT3 tyrosine phosphorylation, clearly indicating that inhibiting 
STAT3 requires an alternative target [80]. Persistent activation of STAT3 downstream of 
IL-6 signaling is well documented in disease progression. While there are attempts at 
inhibiting STAT3, by targeting the SH2 domain or DNA-binding domain, directly inhibiting 
STAT3 remains difficult, as it is a latent transcription factor until activated [81]. Perhaps 
an efficient strategy to limit the DNA-binding activity of the transcription factor is 
distinguishing its activator in specific tissues and malignancies.  
 
1.4. Generation of a Jak-1 Conditional knockout Model 
1.4.1. Rationale for Pursuing the Generation of a Conditional Knockout 
 Since 1998, no published attempts have been made to analyze Janus kinase 1 in 
postnatal development via knockout. In the seminal study by Schreiber, the first two 
coding exons of Jak1 were replaced by a neomycin cassette, rendering a disrupted 
allele [20]. This disruption produced a null protein in both a heterozygous cross as well 
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as a homozygous breeding. This conventional, whole-body knockout resulted in 
offspring that experienced perinatal lethality. Thus, the functional role of Janus kinase in 
adult tissue was unable to be performed. What was observed was momentous, in a way, 
as the study pointed to a non-redundant biological role for Janus kinase 1, in mediating 
the signaling of several subfamilies of cytokine receptors (class II cytokine receptors: 
IFNα/β, IFNy, and IL-10, the yc receptor: IL-2, IL4, IL-9, and the gp130 receptor subunit 
class: IL-6, OSM, LIF). The observations and conclusions were made from assessing 
Jak1 wild type and Jak1-deficient macrophages, embryonic fibroblasts, and 
cardiomyocytes.  
 As JAK1 had been implicated to be central in the signaling node for several 
cytokine receptors, it was left to question whether the same signaling cascades would be 
mediated in a similar way in vivo in postnatal development. To address the biological 
function of JAK1 in postnatal development, a spatial and temporal model to delete Jak1 
would need to be designed.  
 
1.4.2. Construct Design  
 Detailed accounts of generating the conditional knockout mouse model can be 
found in the 2016 publication by Sakamoto, et al [82]. The targeting vector was 
generated using bacterial artificial chromosome (BAC) recombineering as described 
previously by Sakamoto, et al, 2014 [83]. Director of the UNMC Mouse Genome 
Engineering Core Facility, Dr. Channabasavaiah Gurumurthy provided valuable 
assistance to Dr. Sakamoto in the generation of the targeting vector. To construct a 
conditional knockout allele of Jak1 gene, homologous recombination was used to insert 
loxP sites around exon 2 (floxed allele), and was generated in mouse embryonic stem 
(ES) cells at the UNMC Mouse Genome Engineering Core Facility. Thirteen correctly 
targeted ES cell clones were identified and two were injected into C57Bl/6 blastocysts. 
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Chimeric animals were produced and germ line transmission of the Jak1fl/fl allele was 
achieved. Further breeding of heterozygous mice identified offspring with both Jak1 
floxed alleles (homozygous Jak1fl/fl mice). Mice carrying both mutant alleles developed 
normally, regardless of gender and were fertile. 
 
1.4.3. Breeding Scheme and Phenotypic Characteristics 
 Recombination occurs when Cre recombinase is present. The recombinase will 
specifically recognize the loxP sites and will excise the DNA fragment between two 
directly oriented loxP sites. From the Jak1 fl/fl construct design, recombination would 
delete exon 2, causing a frameshift of the coding sequence, resulting in an absence of 
protein.  To analyze whether our recently generated Jak1 conditional knockout mouse 
would phenocopy that of the previously published conventional knockout , the floxed 
allele of Jak1 was transmitted in the germline of MMTV-Cre mice (line A) [84], as the 
developing oocytes express active Cre recombinase [85]. Transgenic female mice 
carrying the MMTV-Cre and Jak1fl/wt genes were bred, activating the Cre recomibinase in 
the oocyte and thereby deleting one allele of Jak1. The progeny were screened by PCR 
and observed that Jak1wt/- mice developed normally and were fertile. These observations 
support the 1998 study of the conventional Jak1 knockout, where one allele deficiency 
did not promote a dominant-negative phenotype. To generate Jak1-null offspring, Jak1 
heterozygous mice (Jak1-/+) were crossed. To rule out early embryonic lethality, fetuses 
at embryonic day 12.5 through 18.5 were collected. In total, 43 embryos were collected 
and were near an expected Mendelian ratio, as 9 (21%) of the embryos were Jak1-
deficient, 22 (51%) were heterozygous, and 12 (28%) were wild type. In our observation 
of the embryos at day 12.5, homozygous null, heterozygous, and wild type were 
indistinguishable from one another. Although, at embryonic day 15.5, 17.5, and 18.5, the 
Jak1-deficient fetuses were noticeably smaller in size compared to wild type embryos. 
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While observing Jak1 knockout offspring, pups survived birth and were able to move 
similar to wild type pups, but had noticeably more difficult time breathing, with longer 
pauses or gasps similar to apnea. Knockout mice perished 30 minutes to 2 hours after 
birth. Similar to Rodig et al., the newly generated Jak1 knockout phenotypically mimics 
the reported conventional deletion.  
 
1.4.4. Molecular Characteristics of a Jak1-deficiency  
 To confirm the deletion of Jak1 on the molecular level, PCR was used to identify 
wild-type or null alleles in developing embryos, and murine embryonic fibroblasts were 
derived from embryonic day 12.5 for primary and immortalized cell cultures. Cells were 
derived from Jak1 wild-type, heterozygous and knockout embryos for biochemical 
analysis (see Materials and Methods: Generation of Murine Embryonic Fibroblasts). The 
MEFs deficient in Jak1 were not exclusively dependent on the kinase for survival in 2D 
culture, as they grew and proliferated at the same rate as the wild type. Immunoblotting 
was performed on the MEF cells, and the Jak1 deletion was confirmed in the 
homozygous null fibroblasts, confirming that the deletion of exon 2 resulted in the 
absence of protein [86]. As well, a minor reduction in protein was seen in the 
heterozygous cells. The total levels of JAK2 remained constant, although interestingly, at 
the steady-state level, the cells exhibited a loss of activated STAT3, as detected by 
Western blot. The loss of tyrosine (T705) phosphorylation was evident, although serine 
phosphorylation (S737) was unchanged, suggesting that a JAK1-independent 
mechanism is needed for serine activation. The predominant modification is tyrosine 
phosphorylation for STATs to localize to the nucleus, and it has been proposed that 
serine and tyrosine activation are not interdependent. In analyzing other members of the 




1.4.5 Conclusions from Generation of the Janus kinase Knockout model 
In conclusion, the generation of the conditional deletion of Jak1 mirrors that of 
the previously reported conventional, whole body knockout of Jak1 [20]. The recently 
generated data from Sakamoto et al., 2016, suggests that this kinase is necessary for 
the tyrosine activation of three members of the STAT family, as analyzed by in vitro data. 
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1.5. Conclusion and Dissertation Hypothesis 
The JAK/STAT pathway has many functions in development and tissue 
homeostasis, yet also contributes to disease progression and maintenance, and thus 
has been a target in cancer. Specifically in breast cancer, the premise that STATs can 
contribute to cancer initiation and survival is well-studied, but the concise identification 
and the biological function of their upstream activators has been less explored. 
Through prior exploration of JAK/STAT signaling in the mammary gland, it is 
evident that the pathway is crucial not only for processes such as growth, proliferation, 
and cell survival, but also for the breakdown and remodeling of the gland via IL-6 class 
inflammatory cytokines (e.g. LIF and OSM). The two members of the Janus kinase 
family that are expressed within the mammary epithelium, JAK1 and JAK2, have 
generally been thought to have redundant functions in STAT activation. This is due, in 
part, to the emphasis on JAK2 in mammary studies and also the lack of data and 
appropriate genetic tool to investigate the postnatal role of JAK1 in development. We 
have demonstrated that JAK2 is exclusively required for the activation of STAT5, 
promoting growth of the gland and also contributing to alveolar proliferation [60]. The 
involution events have characterized STAT3 as the prominent STAT protein driving 
expression of genes necessary for remodeling the gland [36]. Still, the upstream kinase 
responsible for STAT3 activation is unclear, as both JAK1 and JAK2 are thought to 
mediate the inflammatory cytokines. In contrast to the general paradigm, JAK2 may be 
dispensable for involution events and mediating IL-6 class inflammatory cytokines, and 
resulting activation of STAT3. Supporting this premise, we have observed a persistent 
activation of STAT3 in mammary tumor cell lines that are genetically deficient in Jak2 
[80], indicating that another Janus kinase may be responsible for STAT3 signaling. 
Therefore, we hypothesize that the Jak1 signaling cascade is an important factor in 
inflammatory cytokine signaling and has a role in postlactational remodeling of the 
 29 
normal mammary gland and as inflammatory cytokines play a significant role in cancer 
development, Jak1 may contribute to neoplastic transformation and malignant 
progression. To approach these questions, we will first determine whether ablation of 
Jak1 affects normal mammary gland remodeling. Second, we will analyze the 
importance of Jak1 signaling in mammary carcinogenesis. 
The purpose of this work is to identify the molecular contribution of JAK1 to STAT 
activation, characterize the function and biological relevance of JAK1 in adult mammary 




Chapter 2: Materials & Methods 
 






Mouse Colonies and Strains Used 
The use of rodents for studies in this body of work is approved by the Institute for 
Animal Care and Use Committee (IACUC). Mouse colonies were maintained according 
to IACUC protocol and standards, and monitored by UNMC Comparative Medicine. 
Animals were treated fairly and humanely. Premature euthanasia was employed when 
any signs of distress appeared in mice during the course of the studies such as impaired 
movement, pain, and lack or eating or drinking. Mice were first euthanized by applying 
anesthesia by CO2 followed by cervical dislocation, as recommended by American 
Veterinary Medical Association. 
The MMTV-Cre strain was used to target recombination events specifically to the 
mammary gland. The Jak1fl/fl strain was recently generated and used as a littlemate 
control to double transgenic experimental mice MMTV-Cre Jak1fl/fl.  
Tumor studies utilized the MMTV-neu strain, amplifying the neu oncogene in a 
mammary-specific manner. The CAG-lox-CAT-lox-GFP model was utilized as a visual 
aid for recombination events. Athymic nude, FoxN1nu/nu, from National Cancer Institute 
were used for orthotopic transplant studies. 
 
 
Table 2.1. Mouse Models Utilized  
Mouse Model Background Reference 
MMTV-Cre (A line)  FVB Wagner et al., 1997 
MMTV-neu FVB Muller et al., 1988 
Jak1fl/fl FVB Sakamoto et al., 2016 
CAG-lox-CAT-lox-GFP FVB Kawamoto et al., 2000 
NCr-Foxn1nu NCr National Cancer Institute 
 
 
Whole mount analysis 
The thoracic (referred to as number three mammary glands) or the abdominal 
mammary (referred to a number four mammary glands) glands were dissected out and 
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spread onto a glass microscope slide (3” x 1” x 1mm, Fisher Scientific) and placed in 
Carnoy’s fixative solution for at least 1 hour or up to three days. Carnoy’s fixative: 6 parts 
100% EtOH, 3 parts CHCL3, and 1 part glacial acetic acid. Fixative was kept in 50mL 
Falcon tubes, where the tissue on glass slide was placed. Fixative reused. The 
mammary gland on glass slide was then washed in 70% EtOH for 15 minutes and 
gradually changed to distilled water. Gland was rinsed in distilled water for 5 minutes. 
The gland was then placed in Carmine Alum Stain in 4’C overnight or for up to one week 
(depending on stain penetration). Carmine Alum Stain: 1 g Carmine (Sigma C1022) and 
2.5 g aluminum potassium sulfate (Sigma A7167) in 500 mL distilled water and boiled for 
20 minutes. Final volume was adjusted to 500 mL with distilled water. Carmine was 
filtered and a crystal of thymol was added as a preservative. Completed stain was stored 
at 4’C and used for several months. After Carmine Alum stain, gland was washed in 
gradients of EtOH for 15 minutes each (70%, 95%, and 100%). Glands were transferred 
to xylene for 6 hours or up to three days and then mounted with Permount mounting 
medium (Fischer Scientific, SP15-100). Whole mounts were visualized using the Zeiss 
Stereo microscope (Carl Zeiss). 
 
Extracting DNA 
Tissue was gathered for genotyping by snipping 0.5cm from end of mouse tail 
(typically 4 weeks of age) and digested overnight at 56’C in a Digestion Buffer solution. 
Digestion buffer was comprised of Tail Buffer: (for 500mL buffer) 1% SDS (50mL of 10% 
solution), 50nM TrisHCl pH8 (25mL of 1M solution), 100nM NaCl (10mL of 5M solution), 
and 50 mM EdTA (50mL of 0.5M solution) and Proteinase K (PK), 10mg/ml. For each 
sample, 500 uL of Tail buffer and 20 uL of PK were used. DNA was extracted by 
mechanical means, using the AutoGenprep2000 (all reagents used proprietary to 
AutoGen and contain phenol, ethanol, I-Butanol 9%, Iso Amyl Alcohol 0.01%, and 
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isopropanol 40%) and maintained high levels of DNA yield and quality. In the event that 
the mechanical extraction was used, DNA was extracted by hand using the following 
protocol: Each sample (in 1.5mL tube) was suspended in Digestion Buffer (700 uL of Tail 
Buffer and 30 uL of PK) and digested overnight at 56’C. The samples were then briefly 
vortexed and spun down at 13,000 RPM for 20 minutes at room temperature. The 
supernatant was then poured off into new 1.5 mL tube and 600 uL Phenol added 
(Invitrogen, 15513-047). The tube was gently inverted 7 times to mix and centrifuged at 
13,000 RPM for 20 minutes. The top layer (containing water and DNA) was pipetted off 
and placed into new 1.5 mL tube and 600 uL chloroform (Fisher BP1145-1) added, 
inverted 7 times to mix and centrifuged at 13,000 RPM for 20 minutes. The top layer was 
carefully pipetted off and placed into a new 1,5 mL tube and 1 mL of 100% EtOH and 
was added and the tube gently inverted 7 times to precipitate the DNA, and spun at 
13,000 RPM for 20 minutes, The supernatant was poured off and the DNA pellet was 
dried by laying the tube on its side for 15 minutes. 100 uL TE (Fischer Scientific, 
BP2473-1) was added to resuspend the DNA. 
 
Genotyping 
Extracted genomic DNA was then analyzed by polymerase chain reaction (PCR) 
to verify the presence or absence of specific genetic modifications. A single PCR 
reaction was comprised as follows: A final reaction volume of 50uL was made of 32.5uL 
of ddH2O, 10uL of 5x PCR reaction buffer (Promega, M890A), 3uL MgCl2 (25mM, 
Promega, A351H), 1uL of dNTPs (10mM, Invitrogen), 0,5uL each of forward and reverse 
primer (made through IDT, 100pM), 0.5uL of 5U/uL Taq DNA polymerase (Promega, 
M829B), and 1uL of genomic DNA template. Primer sets utilized and PCR conditions in 
Table 2.2. PCR programs were run on a T3 Thermocycler (Biometra). PCR product run 
on a 0.8% agarose gel (BioExpress, E-3119-500), dissolved in 1xTAE buffer (Tris-
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Acetate-EDTA) (Fisher Scientific, BP1332-20) containing ethidium bromide (Ameresco, 
X328-10ML). Gel was visualized using BioDoc-It Imaging System (UVP). 
 
Preparation of murine tissue for analysis 
Histology 
Tissue was removed, cut several times to allow increased buffer penetration, and 
placed in 10% buffered formalin (Fisher Healthcare, 245-684) in a 20 mL scintillation vial 
for 24 hours. After 24 hours, the formalin was poured off and discarded in appropriate 
waste container and the tissue was resuspended in 70% EtOH for long-term storage. 
Tissue was prepared for paraffin embedding by placing tissue in tissue cassette and 
processing and embedding according to manufacturers directions using the Thermo 
Scientific Excelsior AS (an automated system that processes tissue starting from 70% 
EtOH, water, and progressing to dehydrant solution, Clearant solution, and wax). Tissue 
was embedded with the Thermo Scientific Histostar. The embedded tissue was 
sectioned using a microtome, cutting tissue 4 uM thick onto microscope slides (Fisher 
Scientific, 12-550-15). The slides were baked at 56’C overnight and stored in slide 
boxes. 
 
Hematoxylin & Eosin 
The staining protocol has been optimized to produce strong nuclear stain by 
hematoxylin and resilient cytoplasmic stain by eosin. Beginning with paraffin embedded 
tissue sections, deparaffinize in three changes of 100% Xylene (Histo-Clear II, National 
Diagnostics, HS- 202) for 5 minutes each, followed by two 5 minute changes in 100% 
EtOH , and two changes each in 95% EtOH, 3 minutes each. Rinse briefly in distilled 
H2) and incubate slides in Hematoxylin (Fisher HealthCare, 220-100) for 20 minutes. 
Rinse slides in glass slide box briefly in running tap water, avoiding direct running water 
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contact with the slides, until water is clear. Also be sure to use cold water, as warm 
water will fade staining. Dip slides into acid alcohol solution (1%HCl in 70& EtOH) 
followed by a brief rinse in tap water. Next, slowly dip slides into ammonia water solution 
(1 mL NH4OH in 1L H2O), here the sections should darken slightly. Rinse again in tap 
water, briefly, and then incubate in Eosin Y (Statlab, SL98-32) for 1-2 minutes 
dependent on desired intensity. Rinse briefly under tap water. Place slides into 95% 
EtOH for several seconds, here esosin will come off slightly. Move slides to 100% EtOH 
and incubate in two changes for 5 minutes each, to fully dehydrate slides before placing 
in 100% Xylene. Incubate in Xylene for 10 minutes to 1 hour and mount using Permount 
and coverslip. Slides were viewed and using a Zeiss Axio Imager microscope (Carl 
Zeiss) and images captured using SPOT Flex camera and SPOT 5.1 software 
(Diagnostic Instruments). 
 
Immunofluorescence and Immunohistochemisty 
Immunostaining on fixed-formalin paraffin embedded tissue 
The protocol is designed for formalin-fixed paraffin embedded tissue, addressing 
immunofluorescence (IF). Tissues were deparaffinized in 100% Xylene (3 incubations for 
10 minutes each) and rehydrated in decreasing concentration of EtOH (2 incubations in 
100% for 3 minutes each, and one incubation of 3 minutes each of 95%, 90%, 70%, 
50%, and 30%) finishing with a final 5 minute wash in 1xPBS (Fisher Scientific BP399-1, 
diluted 1:10 in ddH2O) for 3 minutes. Slides went through antigen retrieval, using 938 uL 
of Antigen Unmasking Solution (Vectastain, H-3300) into 100 uL ddH2O. Solution was 
pre-warmed first before adding to slides. 45mL of prepared Antigen Unmasking Solution 
were added to slides in 50 mL conical tubes, and heated (avoiding boil) for 20 minutes at 
a power level of 1. Slides were left to cool to room temperature in solution before rinsing 
in 1xPBS for 5 minutes. Slides were marked with hydrophobic pen, and tissue area 
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blocked with 3%BSA  (1.5% BSA, Sigma, A9418-100G, powder, dissolved in 50mL of 1x 
PBS) for 1 hour. Slides were rinsed for five minutes in 1xPBS. Primary antibody added, 
diluted to desired concentration in blocking buffer. Only one section of the two on the 
slide received primary antibody, the other received only blocking buffer for background 
staining control. Primary incubation carried out overnight in a moist chamber at 4°C. The 
following day slides were rinsed three times in 1xPBS for 5 minutes each. Secondary 
antibody was applied to all tissue, diluted in blocking buffer, appropriate to primary 
antibody host and reporter fluorophore. Care was taken to perform tasks in low light to 
avoid diminishing secondary antibody fluorescence. Secondary antibody incubated in 
moist chamber for 1 hour, away from light, at room temperature. Slides washed twice in 
1xPBS for 5 minutes each followed by one wash in ddH2O for 5 minutes to remove salts 
that may increase background staining. One drop of Vectasheild DAPI mounting media 
(Vector, H-1200) was added per tissue and coverslipped. Sealed with clear nail polish, 
and stored away from light at 4°C. Primary and secondary antibodies used for both 
immunofluorescence and IHC listed in Table 2.3 . Slides were then visualized using 
Zeiss Axio Imager A1 (Carl Zeiss) and images taken using SPOT Imaging Software 5.1 
2014. 
To perform immunohistochemistry (IHC), all steps are similar to the IF protocol, 
from deparaffinization and through rehydration.  After rehydration, background 
peroxidase was treated with a 30 minute incubation in a 3% H2O2 (Fisher, H325-500) 
solution in methanol. (EMD Millipore, MX0475-1). Sildes were rinsed and then treated by 
antigen retrieval and blocked as in the IF protocol. Primary antibodies for IHC are listed 
in Table 2.3 and diluted in blocking buffer. Slides were incubated overnight in moist 
chamber in 4°C. The next day, biotinylated secondary antibody was prepared using the 
Vector ABC staining kit (Vector PK-6101, PK-6102), diluted 1:200 in blocking buffer. 
ABC reagent was prepared by adding 1 drop of each reagent A and B into 5 mL of 
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1xPBS, vortexed, and incubated at room temperature for 30 minutes. Slides were rinsed 
of secondary antibody in 1xPBS for 5 minutes and ABC reagent added and incubated for 
30 minutes in a damp chamber at room temperature. Slides were rinsed in 1xPBS for 5 
minutes while DAB reagent (3,3-diaminobenzadine, a peroxidase substrate) was 
prepared (Vector labs, SK-4100). Slides were dried slightly and DAB was added to 
slides and watched as staining intensity developed under light microscope. Reaction 
was terminated by placing slides in tap water. Slides were counterstained in hematoxylin 
for 10 seconds and rinsed with cold tab water. Slides were dehydrated in reverse 
process as the rehydration steps and mounted.  
 
IHC for pSTAT1 
The following protocol was used for the identification of pSTAT1 (Origene pY-
STAT1, TA309955) in mouse tissue. Used IDetect™ Universal Mouse Kit-HRP 
(IDSTM003). IHC protocol was followed through from deparaffinization to rehydration. 
Next, slides were treated with detergent permeabilization, 0.02% Tween 20 in 1xPBS for 
20 minutes, then washed in 1xPBS. Antigen retrieval is same as previously described 
IHC then cooled to room temperature for 1 hour. Slides were then treated for 
endogenous peroxidase with 3% H2O2 in methanol for 20 minutes, then washed 3 times 
in 1xPBS for 3 minutes each. Super Block (part of kit) added for 7 minutes, incubated 
room temperature after circling tissue with hydrophobic pen. Slides washed 3 times in 
1xPBS 3 minutes each. Universal Mouse Block (part of kit) added to tissue, incubated 
for 1 hour, then washed 3 times in 1xPBS. Primary antibody was diluted 1:100 in 1% 
BSA in 1xPBS and incubated overnight at 4°C in moist chamber. Next day slides 
washed 3 times in 1xPBS and biotinylated secondary antibody, Anti-Polyvalent, added 
for 20 minutes (part of kit), incubated at room temperature. Washed 3 times in 1x PBS, 
then HRP (part of kit) added, incubated 20 minutes at room temperature. Washed 3 
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times in 1xPBS, then stained with DAB reagent (prepared as described previously) until 
reaction developed. Counterstain, dehydration, and mounted as described previously. 
 
Immunoblotting Protocol 
Tissue and cells were prepared for Western blot (WB) by resuspending in 
prepared complete lysis buffer. Complete lysis buffer, a mixture of RIPA buffer and 
proteinase inhibitors, is prepared as follows: RIPA buffer: (radioimmunoprecipitation lysis 
buffer, which will lyse cells and solubilize proteins, used for whole cell extracts and 
membrane bound proteins) contains: 0.1% SDS, a denaturing detergent, 0.5% sodium 
deoxycholate for protein/protein disruption, 1% Nonidet P-40, in 1xPBS, stored at 4°C. 
Proteinase inhibitors are as follows: Sodium orthovanadate (Sigma, S6508), PMSF 
(Stock solution of 10mg/mL in isopropanol): Leupetin (Midwest Scientific, J580-2, stock 
at 10mg/mL in ddH2O), Aprotinin (Sigma #A6279), and Sodium fluoride (Fisher 
Scientific, S299-100, stock solution 1M in ddH2O). Quantities of reagents to add for 
complete lysis buffer are as follows: For final volume of 500 uL, 471 uL of RIPA buffer, 9 
uL of PMSF, and 5 uL each of aprotinin, leupeptin, sodium orthovanadate, and sodium 
fluoride were combined and vortexed. 
Cell pellets were prepared for immunoblot by resuspending in 50-150 uL of 
complete lysis buffer in 1.5 mL tubes, on ice, and lysed using the Fisher Scientific Model 
500 Sonic Dismembrator, amplitude set to 13 and pulsed for 3 seconds, twice, with 
resting 30 seconds on ice in between. Cells were placed on ice for 20 minutes followed 
by centrifugation at 13,000 RPM for 30 minutes at 4°C. The resulting supernatant was 
moved to a new 1.5 mL tube and quantified by Bradford reaction using BSA protein 
standard in Coomassie Plus Protein Assay Reagent (Thermo Scientific, 1856210)  for 
standard curve. 25-75 ug of protein was prepared for analysis by adding 25 uL of Tris-
Glycine SDS sample buffer (Novex, LC2676) and 1 uL of beta-mercaptoethanol (Fisher 
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Scientific, BP176-100) to each sample and boiled for 10 minutes at 100’C. Samples 
were placed immediately on ice before loaded onto 4-20% SDS-PAGE gel (Invitrogen, 
XP04200BOX). Gels were run for 1 hour at 80 volts followed by120 volts for 1.5 hours. 
Gel was transferred onto solid support PVDF membrane filter paper, 0.2um pore size 
(Novex, LC2002). Transfer was run at 17mAMPs for 1 hour followed by 30mAMPs for 1 
hour. Membrane blocking was in 5% dry milk in 1xTBST (Tris-buffered saline with 0.05% 
Tween-20) buffer or 3% BSA in 1xTBST for phosphorylation-detecting antibodies, for 1 
hour at room temperature, rocking. Membranes were washed in 1xTBST and primary 
antibody applied in appropriate concentration for overnight incubation, rocking, at 4°C. 
Next day membranes washed 3 times 5 minutes each before HRP-conjugated 
secondary antibody added in appropriate concentration in blocking buffer for 1 hour, 
room temperature. Protein was detected using the ECL chemiluminescence kit (GE, 
Amersham, RPN2106). For further probing on same membrane, membranes stripped 
using 0.2M sodium hydroxide solution for 15 minutes. Film used for exposure 
(BioExpress, F-9029-8X10) List of antibodies used, Table 2.3. The Janus kinase 1 
antibody was generated in the lab of Dr. Hallgeir Rui and kindly shared. Sodium azide 
(Sigma, S8032) was used to extend primary antibody use in buffer (several crystals 
added per 10mL antibody cocktail prepared), this aided in reusing antibody several times 
before discarding. 
Tissue was prepared for WB by suspending in complete lysis buffer, 200- 500uL, 
dependent on tissue size and homogenized twice, 5 seconds each, to dissociate cells, 
samples incubated on ice for 20 minutes. The remaining steps follow protocol written 
above. 
 
Generating Expression Vectors 
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To facilitate expression of selection markers or target genes, the following vector 
constructs were used: pHIV-dTomato (Gift of Bryan Welm, Addgene plasmid #21374), 
pHIV-ZsGreen (Gift of Bryan Welm and Zena Werb, Addgne plasmid #1812) [87]. The 
pHIV-Luciferase-ZsGreen was generated using the pHIV-ZsGreen construct was 
digested with BamHI and Not1 overnight, the next day calf intestinal phosphatase (CIP) 
was added for one hour to limit self-ligation. The T7-IRES-Luciferase (cloned by Kay-
Uwe Wagner, PhD) luciferase insert was PCR amplified and digested with BamHI and 
Not1. The backbone and insert were ligated overnight and transformed in Top10 cells. 
Clone “g” was used for virus production.  
The shJAK1 was generated using shJAK1 (TRCN0000003102 and 
TRCN0000003105) and cloning into the Tet-pLKO-puro (Gift from Dmitri 
Wiederschain, Addgene #21915) [88], with AgeI and EcoRI.  
The pHIV-FOS-dTomato was generated using the pHIV dTomato construct, 
digested with HbaI and XbaI overnight. The pcDNA3-FLAG-Fos WT was a gift from John 
Blenis (Addgene #8966) [89], and was digested with Asp718, then subsequently 
digested with Xba1. The backbone and insert were ligated overnight and transformed in 
DH5α cells. Virus was made from DNA isolated from clone “A”. The pHIV-caSTAT3-
dTomato was generated using the pHIV dTomato backbone and STAT3-C (pMXs-Stat3-
C was a gift from Shinya Yamanaka [Addgene plasmid # 13373] [90]). Not1 site was 
added to 5’ end of STAT3-C construct by PCR, as well as BamHI cloned into 3’ 
terminus, following amplification the DNA was digested with BamHI and NotI. dTomato 
was digested with BamHI and NotI, followed by CIP treatment. Insert and backbone 
were ligated overnight and transformed in DH5α cells. Proceeded with clone 9 to make 
virus after sequencing. The pWZL Neo Myr Flag MAP3K8 was a gift from William Hahn 
& Jean Zhao (Addgene plasmid # 20521) [91], and was cloned into the pHIV-dTomato 
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Virus was produced by transfecting low-passage 293T cells (ATCC) using 
Lipofectamine (Invitrogen 2000,11668-019) and collecting supernatant over the course 
of three days. Collected virus was filtered using 0.45uM filter by syringe and aliquoted in 
4mL increments and frozen at -80C. To infect cells, virus was thawed prior to used and 
Polybrene was added. Virus was added to cells plated in 6-well plates and centrifuged at 
1200RPM for 90 minutes at room temperature. 48 hours later, successful infection could 
be identified in cells expressing fluorescent markers and sorted at the UNMC Flow 
Cytometry Research Facility. Antibiotic selectable markers could also be treated for at 
the 48 hour time point, post infection. Puromycin would begin at 2-5ug concentration 
added to media. 
 
In vivo Bioluminescence Imaging  
Expression of luciferase reporters was analyzed using the in vivo 
bioluminescence imaging system (IVIS200). Animals were injected intraperitoneally 5 
minutes prior to imaging with luciferin. 1mg D-Luciferin mixed with 1mL of 2xPBS, [92], 
and  (Xenogen, XR-1001) and dosed at 150mg/kg of body weight. Equipped with the 
IVIS200 is an XGI-8 gas anesthesia system, which was used at a 2.5% Isoflurane flow 
rate (Butler Schein, 029404). Mice were anesthetized immediately prior to and during 




Mammary tumors were excised in sterile environment from tumor-bearing mice. 
Tumors were either minced and transplanted immediately or frozen. Tissue was minced 
and immediately put into Recovery Cell Culture freezing media (Gibco, 12648-010) and 
stored at -80C until later transplantation. Frozen tissue used for transplant was quickly 
thawed in 42’C water bath and resuspended in DMEM growth media, spun down, 
resuspended again in DMEM growth media and taken for transplant. For transplantation, 
0.1cm fragment was transplanted into both number four mammary glands of Athymic 
nude mice, under anesthesia. Incisions were closed by staples, which were removed 
after 7 days. Tumors were monitored for growth weekly using calipers.  
Murine mammary tumor cell lines were harvested by trypsinization, counted, 
resuspended in sterile 1xPBS and 1x105-1x106 tumor cells were injected into both 
number four mammary glands of Athymic nude mice. Tumor size was monitored for 
growth weekly using calipers. 
Mammary gland transplants were achieved using viable frozen fragments of 
target epithelium (example, BIM/BMF double knockout glands). Tissue was minced into 
1 mm3 pieces and transplanted into the cleared mammary fat pad of both thoracic glands 
of 21 day-old female Athymic nude mice. Tissue was permitted to engraft, forming ductal 
structures, for 12 weeks. Females were bred and glands collected immediately after birth 
or time points during involution. 
 
Whole Genome RNA-Sequencing 
The genome wide survey of the transcriptome was achieved by first extracting 
RNA from mammary tissue or collected cell lines using the RNeasy Mini Kit (Qiagen, 
74134). RNA was quantified using NanoDrop, and run on a gel to assess RNA quality. 
Samples were processed using TruSeq kit (RS-122-9001DOC  ). Generated cDNA was 
quantified on a Qubit Flurorometer and assayed for quality control using the BioAnalyzer 
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2100. Sequencing was perfomred using the HiSeq2000 (Illumina). In silico analysis was 
performed on the Tusker Supercomputer (Lincoln, NE) using the Unix commands. 
FASTQC (computes and provides quality profile of sequencing reads) demonstrated a 
Phred score of over 32 for all samples. Tuxedo Tools (index of samtools, open source 
bioconductor) were used in order to analyze the single-end reads: TopHat (uses Bowtie 
for read alignment, mm10 for mouse and hg38 for human, and splice junction mapping. 
Output as bam files), Cufflinks (assemble transcriptomes from RNA-Seq data and 
quantifies their expression) followed by Cuffmerge (merges individual transcriptomes 
into master transcriptomes, required for differential expression analysis). Cuffquant (the 
output is cxb file) followed by Cuffdiff (compares expression levels of genes and 
transcripts) and Cuffnorm (creates a table of normalized FPKM values).  FPKM 
(Fragments Per Kilbase of transcript per Million mapped reads) values were used to 
analyze the differential transcript expression between control and experimental groups. 
Gene Set Enrichment Analysis (GSEA) was performed from output FPKM valued, 
comparing whole gene sets or pathways. For the analysis of the control tumor cell lines 
versus the Jak1 knockout cell lines GSEA permutation type parameters were set to 
utilize the phenotype permutation. Analysis of the paired isogenic mammary tumor cell 
lines required use of the gene_set permutation, as the program does not allow for the 
phenotype permutation in a sample size less than 3 per group. Individual genes were 
viewed using the Broad Institute’s Integrative Genomic Viewer (IGV). 
Chromatin Immunoprecipitation Sequencing (ChIP-Seq) 
ChIP seq analysis was performed for the binding of STAT3 and STAT5, using 
mammary tissue from mid-pregnant females. In brief, snap-frozen tissue was 
homogenized and DNA was cross-linked using 1% formaldehyde. Nuclei were isolated 
in Farnham lysis buffer, samples were sonicated, centrifuged, and suspended in RIPA 
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buffer. Lysate was quantified and 600-1000ug lysate were added to Dynabead antibody 
complexes. Antibodies were ChIP-certified against STAT3 and STAT5. Samples were 
reversed-crosslinked and was DNA purified before libraries were generated using 
TruSeq ChIP sample kit (Illumina). 
 
ChIP and Quantitative Real-time PCR (RT-PCR) 
Following RNA extraction using the RNeasy Mini Kit (Qiagen, 74134), 
complementary DNA (cDNA) was synthesized using Superscript cDNA synthesis kit 
(protocol). ChIP was performed using primers against STAT3, STAT5, and isotype-
matched control IgG as described previously [58, 93]. STAT binding was assessed for 
Bim and Bcl2l11 using gene-specific primers. Background and normalization was tested 
using non-promoter sites as described previously [93]. Quantitative RT-PCR was carried 
out using the C1000 Thermal Cycler (BioRad System, CFX96-Real Time). Conditions 
and primers used listed in Table 2.2. 
 
Statistical Analysis 
Graphs and accompanying statistics were prepared using Prism 6 software 
(GraphPad Software). Data computed as the mean ±SD, unless otherwise noted. The 
unpaired Student t test was used to compare data sets and verifying significance. A P 
value of < 0.05 was ruled significant. 
 
Cell culture 
Murine epithelial and tumor cell were maintained in the following growth media: 
DMEM/F12 powder (12400-024), 10 ug/mL of Insulin (Gibco, 12585-014), 10 ng/mL 
EGF (Life Technologies, E3476), 1 mg/mL BSA (Sigma, A9576), 5 ug/ML linoleic acid 
complex, 50ug/mL gentamicin (Gibco, 15750-060), 0.25 units/mL fungizone (Gibco,##), 
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20mg/mL FBS (Atlas, F-0500-A), 100U/mL Pen/Strep (Penicillin Streptomycin) (Gibco, 
12140-122), 1.5g sodium bicarbonate (Mallinckrodt Chemicals, 7412-12), beta-
mercaptoethanol (Gibco, 21985-023). Media was adjusted to a pH of 7.6 with NaOH and 
filter sterilized using 0.22 uM filter (Millipore, SCGPS05RE). 0.05% Trypsin used for cell 
passage (Gibco, 25300-054). 
 
Generation of Primary Tumor Cell Lines 
Preparation of digestion buffer: 
DMEM/F12    20 mL 
100 units/mL pen-strep  200 uL 
100 ug/mL gentamicin  40 uL 
0.75 units/mL Fungizone  60 uL 
2 mg/mL collagenase   1 mL 
100 units/mL hyaluronidase   300 uL 
 
Tissue was removed by sterile means and was minced, placed in 20mL of 
digestion buffer in 50mL Falcon tube, and incubated in 37C hybridization oven, rotating 
speed 11 for 1-3 hours, or until dissociation was evident. Cells were centrifuged 
1200RPM for 5 minutes at room temperature and supernatant removed by suction. Cells 
were washed by resuspension in growth media for a total of 5 washes. Following final 
wash, cells resuspended in 6mL of growth media and strained into 3 wells of 6-well plate 
(2 mL each). The filter was then flipped over and washed off three times with 2mL each 
growth media into the remaining 3 wells, as this captured the organoid cell clusters for 
growth. Cells were maintained in 10% FBS for 6-8 weeks followed by a decrease to 
5%FBS-containing growth media. During this time, fibroblast cells were removed by 
partial trypsin (1mL trypsin added to a well of 6-well plate, monitored at room 
temperature under light microscope, light agitation was applied to lift fibroblast-like cells. 
Once lifted, trypsin removed by suction and growth media applied). Cells selected for 
growth were epithelial in appearance (cobblestone structure versus spindle cells). 
 
Generation of Murine Embryonic Fibroblasts 
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Mouse embryonic fibroblasts (MEFs) were generated from Jak1-deficient 
embryos at embryonic day 12.5, following the initial primary cell generation technique 
described above. MEFs were cultured in DMEM, 10% FBS, 2 mM glutamine, 0.1 mM 
nonessential amino acids, 10 ug mL-1 streptomycin. MEFs were immortalized by serial 
passaging.  
 
Treatment of cells 
Cells were serum-starved (Growth media without FBS) for 16 hours prior to 
cytokine stimulation. Treatment included: ovine GH (20nM), recombinant mouse IL-4 
(50ng/mL, BD Phamingen), recombinant mouse OSM (25ng/mL, R&D Systems), LIF 
(103 U/mL, Millipore), for 15 minutes at 37C, followed by cell collection. Ovine GH was a 
gift by Dr. A.F. Parlow (National Hormone and Peptide Program, Harbor-UCLA Medical 
Center, Torrance, CA) under sponsorship of the National Hormone and Pituitary 
Program, NIDD (National Institutes of Health). 
 
shRNA induced by Doxycyline (Dox) 
Treating cells with Doxycyline hyclate (Sigma D9891-25G): stock solution was 




Cells were trypsinized, resuspended in serum-free media, and counted using 
hemacytometer. Using a 24-well plate, 1mL of serum-rich media (20% FBS) was added. 
An 8 micron, insert was placed in well (8um, Corning, 353097) and desired amount of 
cells resuspended in 200uL of serum-free media added (2.5x104 cells/insert) and 
incubated cells for 18-24 hours. The following day migrated cells were collected and 
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stained by taking the insert, washing 3 times in cold 1xPBS, and consecutively dipping 
the insert 15 times each in fixative, cytoplasmic stain, and nuclear stain. The staining 
was achieved using Hema 3 Stat Pack (Fisher Scientific, 123-869). The back of the 
insert was wiped with a cotton swab to remove cells that did not migrate. Permount was 
added to a microscope slide and the membrane insert was cut out with a razor blade 
and placed in the Permount and coverslip added. Migrated cells were counted under 
200x magnification the average of three field views was calculated and recorded as cells 
per 1x1mm2. 
 
Flow Cytometry Analysis 
Cells were trypsinized, and washed twice in buffer (1% FBS in 1x PBS) and 
counted. A total of 1x105 cells were stained for surface markers. Cells were spun down 
and resuspended in 150 uL of buffer, antibody added, vortexed gently and incubated for 
30 minutes on ice, protected from light. Following antibody incubated, cells were 
centrifuged at 4K RPM, for 5 minutes. Cells were resuspended in 1 mL of buffer to wash, 
and centrifuged, repeated twice. After the final wash, cells were strained into FACS 
tubes and analyzed. Appropriate controls were used, such as unstained samples and 
fluorescence controls. Flow cytometry was performed using the LSRII and analyzed 
using BD FACSdiva 8.0.1 software (BD Biosciences). Antibodies used were confirmed 
for flow analysis: CD61 APC Conjugate (Life technologies). OneComp eBeads 










Table 2.2. Primer Sets for Genotyping and qRT-PCR 
Target Lab ID Direction Sequence: 5’->3’ PCR Conditions 
MMTV-neu 1259 Forward TTTCCTGCAGCAGCCTACGC 
Step 1: 96C, 3 min 
Step 2: 96C, 1 min. 
Step 3: 60C, 1 min 
Step 4: 72C, 1 min 
(to Step 2, 32x) 
Step 5: 72C, 5 min 
Step 6: 4C, pause 
 
1260 Reverse CGGAAC CCACATCAGGCC 
MMTV-Cre 580 Forward GATGTGAGACAAGTGGTTTCCTGAC 
1785 Reverse CATCACTCGTTGCATCGACC 
Jak1 fl/wt 2411 Forward GAGACAGGATACCTGGTGGCTTGG 
2412 Reverse GTAGCAGTCCTGGACATTGAGTCC 
Jak1 null 2411 Forward GAGACAGGATACCTGGTGGCTTGG 
2372 Reverse AGGTGCCACTCCCACTGTCCTTTCC 
CAG-GFP 2004 Forward GGCTCTAGAGCCTCTGCTAACC 
2211 Reverse GCCATTGGGATATATCAACGGTG 
ChIP 
Background 
2144 Forward GGCCACTCATCAGCTCTCACCCATAC 
Step 1: 95C, 3 min. 
Step 2: 95C , 30 sec. 
Step 3: 60C, 30 sec. 
Step 4: 70C, 30 sec. 
(to Step 2, 39x) 
2145 Reverse GCTCTCTCAAGCCTCCAGCAAAAACC 
Bcl2l11 GAS #1 2517 Forward GCGACGAAGAATCTCGCTTGAGGCGC 
2519 Reverse GTGTTTACCCTAGTGTCTTGGCCTG 
Bcl2l11 GAS #2 2520 Forward ATCAGTGAAAGTTAGTTCTCTGCCTTC 
2521 Reverse CACAGATTTACCTACAGGCAACCTGAT 
BMF GAS #1 2512 Forward CCAGTCCTCTATAAAGTAATTCCTTGG 
2513 Reverse CAGGTAGATTCAGGTCAGATTGCAGAG 
BMF GAS #2 2514 Forward CTGGCTCTGTTTATATCACTCGCTATA 






Table 2.3. Antibodies for Immunoblotting and Immunostaining 
Target Source Catalog # Application 
STAT1 Santa Cruz SC-592 WB 
pY-STAT1 Origene TA309955 WB, IHC 
pS-STAT1 Abcam Ab109461 WB 
STAT3 Cell Signaling 9139S WB 
pY-STAT3 Cell Signaling 9145S WB, IHC 
STAT5 Santa Cruz SC-836 WB 
pY-STAT5 Cell Signaling 9351S WB, IHC 
STAT6 Santa Cruz SC-981 WB 
pY-STAT6 Abcam Ab54461 WB 
GAPDH Cell Signaling 5174 WB 
b- ACTIN Santa Cruz I-19 WB 
pTyr Cell Signaling 05-321 WB 
c-FOS Abcam Ab7963 WB, IF 
RUNX1 Origene TA309955 WB, IF 
BMF Enzo 17C2 WB 
BIM Abcam Ab7888 WB 
JAK1 Dr. Hallgeir Rui (Gift) WB 
JAK2 Cell Signaling 3229 WB 
WFDC5 LifeSpan LS-C297015 WB 









CD14 Abcam Ab182032 IF 
OSMR Santa Cruz SC-8494 WB 
BCL3 Biossuas Bs-6591R IF 
TUBULIN Epitomics 1878-1 WB 
PDGFRA Boster PB9771 IF 
SOCS1 Boster PA1074 IF 






Chapter 3: Janus kinase 1 mediates inflammatory cytokine signaling during 
mammary gland involution 
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and K.-U. Wagner (2016): Janus kinase 1 is essential for inflammatory cytokine signaling 
and mammary gland remodeling. 








 The postnatal growth and development of the mammary gland is dependent on 
hormones, growth factors, and locally derived cytokines to induce ductal elongation and 
branching, functional differentiation of the epithelium, and the postlactational remodeling 
of the gland. Initially, estrogen serves to induce ductal elongation after puberty. 
Meanwhile, during pregnancy and nursing offspring progesterone and prolactin (PRL) 
promote the functional differentiation, proliferation, and maintain cell-sustaining signals. 
Following weaning of the offspring, a decrease in the circulating levels of prolactin along 
with milk stasis initiate the local production of interleukin-6 (IL-6)-class cytokines. 
Notably, Oncostatin M (OSM) and leukemia inhibitory factor (LIF) are the prominent 
members of the IL-6 class that initiate the cascade of intracellular events that culminate 
in the programmed cell death and removal of select terminally differentiated epithelium. 
 The ligands such as PRL and OSM rely on nonreceptor associated Janus 
kinases to activate their corresponding receptor, mediating the signal and 
phosphorylating subsequent signal transducers and activators of transcription (STATs). 
Activated STATs function to bind to the DNA, altering the transcriptional profile and 
molecular events of the cells. In the family of seven STAT members (STAT1, 2, 3, 4, 5a, 
5b, and 6), five are expressed within the mammary epithelium (STATs 1,3, 5a/b, and 6), 
although they are activated a defined stages of mammary gland development. While 
STAT1 and STAT6 play subordinate role in development, the effects of STAT5 and 
STAT3 are robust. During pregnancy and lactation, STAT5 responds to the increase of 
PRL, and through its activation by JAK2, drives the transcription of genes associated 
with proliferation and differentiation. Contrasting the cell-sustaining signals, the drastic 
physiological event of involution is characterized by a decrease in STAT5 activation and 
surge in the phosphorylation of STAT3. In response to the cytokines LIF and OSM, 
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STAT3 is driven to the nucleus and upregulates genes associated with matrix 
remodeling and apoptosis.  
 The contribution of STATs to mammary gland development has been well 
studied, although curiously, little has been investigated on their upstream Janus kinase 
activators. In the family of four Janus kinases, two are expressed within the mammary 
epithelium as JAK3 and Tyk2 are primarily restricted to the hematopoietic system while 
JAK1 and JAK2 have increased ubiquitous expression. The functional role of JAK2 in 
the mammary gland has been established through the development of conditional 
knockouts, demonstrating its crucial role in mediating signaling of PRL to activate STAT5 
for alveologenesis as well as differentiation of the mammary epithelium. Conversely, the 
role of JAK1 has not been addressed in adult organ development, and specifically, the 
STATs activated during mammary gland development and sequential STAT activation is 
unknown. 
 We demonstrate, for the first time, the analysis of a conditional deletion of JAK1 
in a mammary –specific manner. The results support a nonredundant role for JAK1 in 
activating STAT1, 3, and 6, and demonstrate the biologically relevant role for JAK1 in 




JAK1 expression levels in the virgin and pregnant female mammary gland parallel 
with phosphorylation of STAT1 and STAT6 as well as STAT3 activation during 
involution. 
Previous studies have explored the biological significance of five of the seven 
STAT proteins (STAT1, STAT3, STAT5a, STAT5b, and STAT6) during mammary gland 
development. To identify changes in STAT activation in the context of JAK1 expression 
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in the mammary gland, we followed protein expression and activation status of the five 
STATs along with JAK1 throughout a complete postnatal development cycle. Mammary 
tissues from virgin glands, several time points during pregnancy, lactation, and involution 
(i.e., day 2 post-weaning) were analyzed by immunoblot (Fig. 3.1A). While all of the 
STATs are expressed at nearly consistent levels throughout the development cycle, as 
indicated by total protein levels, their various windows of activation may suggest differing 
upstream activators. STAT1 phosphorylation is prominent during virgin state and early to 
mid-pregnancy before declining during lactation and remaining low during involution. 
Active STAT6 displayed low levels throughout the whole development cycle, declining 
during involution. STAT5 was robustly phosphorylated during mid-pregnancy and 
lactation, and decline sharply at the onset of involution. In near-contrast, active STAT3 
was observed during pregnancy, decreased during late pregnancy and lactation, but 
prominently increased during involution. The expression of JAK1 was seen during virgin 
and stages of pregnancy, and mirroring STAT3 activation, also fell during late pregnancy 
and lactation yet increased during involution. The STATs demonstrate activity during 
mid-pregnancy, although the activation of STAT1 and STAT6 follow the expression of 
JAK1 during the virgin stage and pregnancy, as well as STAT3 activation coinciding with 
JAK1 expression during involution event. 
 
JAK1 mediates cytokine signaling to activate STAT1, STAT3, and STAT6 but not 
STAT5 in embryonic fibroblasts in the mammary gland epithelium. 
 In order to investigate the biologically relevant functions of JAK1 during postnatal 
and adult development, we used the previously described conditional knockout model for 
Jak1 [82]. In summary, the gene-targeted Cre/lox-based system inserted loxP sites 
upstream and downstream of the second coding exon of Jak1, and employed a 
neomycin selection marker in intron 3 which did not cause phenotypic abnormalities in 
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homozygous mice. Resulting Jak1fl/fl mice were comparable and indistinguishable to wild 
type controls (Jak1+/+). To validate the null allele during embryogenesis, the Jak1 fl/fl was 
recombined in the female germ line. The resulting deletion of Jak1 led to perinatal 
lethality in newborn homozygous mice. Embryonic murine fibroblasts were derived from 
homozygous JAK1-knockout embryos at embryonic day 12.5 as well as from 
heterozygous embryos and wild type controls, to assess STAT activation. The deletion 
of the Jak1 second coding exon causes a frameshift of the coding sequence and results 
in the absence of the JAK1 protein without a compensatory upregulation by JAK2 (Fig. 
3.1B). In the absence of JAK1, cells displayed a drastic decrease in the tyrosine 
activation of STAT1 and STAT3, although STAT1 serine phosphorylation on S727 was 
preserved, indicating that the two events may occur independently of each other. 
Stimulation of cells by IL-4 and GH demonstrated that STAT6 relies on JAK1 for IL-4-
induced signaling, conversely STAT5 activation by growth hormone stimulation was 
unperturbed by a loss of JAK1 (Fig. 3.1C). 
 For the analysis of JAK1 specifically in the mammary gland, a cohort of female 
mice were generated carrying the MMTV-Cre transgene in a Jak1-floxed homozygous 
background. Littermate controls carried the homozygous Jak1, but lacked Cre 
recombinase. Mammary glands from the experimental and control group were compared 
at gestation day 14.5, a point where all STAT proteins exhibit various activity (Fig. 3.1A). 
The architecture of the glands were similar and a Jak1 deficiency appeared to have little 
effect on alveoli differentiation. Although, analysis by immunohistochemistry indicated a 
loss of pSTAT3 activity in the epithelial compartment, meanwhile active tyrosine-
phosphorylated STAT5 was unaffected (Fig. 3.1D). To understand the activation of 
STAT1, STAT3, and STAT6, mammary epithelial organoids were freshly prepared and 
treated for 20 minutes with OSM and IL-4 (Fig. 3.1E). Similar to the initial studies in 
 56 
fibroblasts, an absence of Jak1 uncoupled ligands from downstream mediators, STAT1, 
STAT3, and STAT6.  
 
A deficiency in JAK1 leads to impaired postlactational mammary gland 
remodeling. 
 To reveal the biological functions of JAK1 throughout mammogenesis, we 
examined the composition and morphology of mammary glands from tissue of JAK1 
conditional knockout females and controls during a complete gestation cycle. A GFP-
based reporter transgene for Cre recombinase demonstrated that deletion of Jak1 by 
MMTV-Cre occurred throughout the ductal system (Fig. 3.2A) and indicated no negative 
selection prior to pregnancy. Deficiency of JAK1 also had no effect on ductal elongation 
or branching. Even though JAK1 contributes to the activation of STAT6, which is 
implicated in alveologenesis, no defects were observed during pregnancy. Experimental 
females were also able to lactate effectively compared to controls, supporting offspring 
until weaning. Histologically, the glands during lactation were similar between the two 
groups (Fig. 3.2B, left) and there was no remarkable differane at 24 hours post-weaning 
(Fig. 3.2B, middle). Strikingly, JAK1-defienct females displayed a pronounced delay in 
postlactational remodeling at 3 days post-weaning (Fig. 3.2B, right) and extended into 
day 5 of the remodeling process (Fig. 3.2C, left). The impairment of effective remodeling 
was also confirmed in a second mammary-specific model, WAP-Cre, for the deletion of 
Jak1 (Fig. 3.2C, right), where recombination of the target gene occurs in differentiated 
alveolar cells during late pregnancy and lactation. 
Deletion of JAK1 uncouples gp130-mediated signaling though IL-6-class cytokine 
receptor complexes from its downstream effector, STAT3. 
 The most dramatic switch in tyrosine phosphorylation of STAT3 and STAT5 
occurs between the physiology events of lactation and involution (Fig. 3.1A). To confirm, 
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immunostaining was performed demonstrating the high levels of nuclear STAT5 in the 
lactating glands, present in both control and JAK1-knockout female mice, which then 
decreased 24 hours into the remodeling phase (FIG. 3.3A). Although few, noticeable 
pSTAT5 staining was observed in the nucleus of JAK1-deficient glands within the first 24 
hours of involution. In contrast to the strong nuclear STAT5 staining, nuclear 
accumulation of tyrosine-phosphorylated STAT3 was dramatically decreased in the 
JAK1-knockout female glands in the initial stages of involution. This striking molecular 
phenotype along with our previous observations that the expression of JAK1 is 
increased during the onset of involution, suggests that JAK1 plays a crucial role in 
mediating the signaling events necessary for remodeling and activation of STAT3 in the 
mammary gland. 
 The two IL-6 class inflammatory cytokines that initiate the signaling of remodeling 
events in the mammary gland signal through specific ligand-receptor complexes that 
share the glycoprotein 130 (gp130) signal transduction unit, culminating in the activation 
of STAT3 for the involution of the mammary gland. To assess the importance of JAK1 as 
a mediator of signaling through gp130, wild type embryonic fibroblasts along with those 
hetero or homozygous Jak1-deficient were treated with OSM and LIF.  The activation of 
STAT1 and STAT3 were tested for activation and the results by immunoblot 
demonstrate the prominent role of JAK1 for mediating the IL-6-class ligands, as a lack of 
JAK1 uncouples the activation of STAT1 and STAT3 from the inflammatory cytokines 
(Fig. 3.3B). To translate the in vitro data to the mammary gland, virgin female mice were 
injected with both OSM and LIF before gland were collected and analyzed by 
immunofluorescent staining of pSTAT3 (Fig. 3.3C). The strong staining in the wild type 
glands of OSM and LIF indicate active STAT3 being driven to the nucleus, as well as a 
presence in the surround stroma (Fig. 3.3C, left). Conversely, JAK1-deficient females 
treated with cytokines have a failure of active and nuclear STAT3, although 
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phosphorylated STAT3 is evident in the stroma of the knockout female glands (Fig. 
3.3C, right). The active STAT3 in the surrounding stroma serves as an internal positive 
control, wild type in JAK1, as the Cre recombinase is only active within the mammary 
epithelium. Both the studies in JAK1-deficient fibroblasts and mammary gland-specific 
deletion indicate that Janus kinase 1 is the dominant tyrosine kinase to mediate 
signaling through gp130-recpetor complexes in response to inflammatory cytokines. 
 
Ablation of Jak1 produced deregulated expression of downstream target genes 
associated with the acute-phase response, inflammation, wound healing, and 
programmed cell death. 
 To further explore the downstream effect and mechanism that a Jak1-deficiency 
causes in mammary gland remodeling, we performed genome-wide RNA-Seq analysis 
comparing tissue from lactating glands to involuting mammary tissue lacking JAK1 and 
wild-type controls. First, we focused on comparing wild-type lactating mammary gland 
tissue to the involuting mammary gland, observing the genes and pathways are 
upregulated during the remodeling phase. Next, we concentrated on identifying genes 
that demonstrated a lack of normal expression during involution with an absence of 
JAK1. The initial comparison between three wild-type lactating and involuting mice 
revealed that 1.131 genes had a 2-fold or higher upregulation during involution and 
1,378 genes were downregulated. Supporting the phenotype and stage of 
mammogenesis, a distinct reduction in expression of genes linked to proliferation and 
cell survival signaling driven by JAK2/STAT5 coincided with an increased expression of 
genes associated with inflammatory signaling. The known targets of PRL and 
JAK2/STAT5 signaling such Socs2, Ccnd1, Akt1 were downregulated in the involution 
tissue, while an increased expression of Lif, Osmr, Stat3, and Socs3 was seen. The 
cytokine receptor switch between the two phases of lactation and involution, as well as a 
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synchronous exchange of the JAK/STAT pathway are illustrated by gene set enrichment 
analyses (GSEAs) of the RNA-Seq datasets (Fig. 3.4A). We also observed an increased 
expression of transforming growth factor B signaling and apoptosis during involution, as 
well as deregulated expression of NF-kB signaling and upregulated expression of the 
tumor necrosis factor receptor superfamily, particularly Tnfrsf1A, Tnfrsf10B, and 
Tnfrsf21. 
 To identify the genes deregulated during involution in a JAK1-dependant manner, 
the gene expression profiles for four conditional knockout mice were compared with 
three wild-type controls at the second day of involution. Only 135 genes displayed a 2-
fold or more deregulation expression, while 203 genes resulted in an increased 
expression. Consistent with what we observe at the protein level, genes that 
demonstrated deregulation in JAK1-deficient glands include Stat3 itself, as well as 
known STAT3 targets such as Socs3, Osmr, and Bcl3 (Fig. 3.4B). Also consistent with 
the STAT3-deficient mice [63], we observe a reduced expression in genes associated 
with inflammation, acute-phase response (Cd14, Saa1/2, and Lrg1) and wound healing 
(Chi3L1). Together with the known targets of STAT3, we found Runx1 and c-Fos to be 
deregulated, as a lack of increased expression was seen compared to their dramatic rise 
observed in the involution tissue. A new JAK1-dependant milk protein was also found, 
the WAP four-disulfide core domain protein (Wfdc5), which was found upregulated 
during involution and is unlike the milk protein WAP that decreases over the same time, 
Interestingly we also discovered several JAK1-dependant genes that regulate cell 
survival and apoptosis. Their downregulation could be responsible for the lack of 
remodeling cell death in the mammary epithelium. These candidate genes include the 
death receptor 6 gene (Tnfsf21) and the tumor susceptibility gene Tpl2 (Map3k8). 
Although, the most consistently deregulated proapoptotic factor was, Bmf, a gene 
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encoding for the Bcl2-modifying factor and BH3-only protein. Related to BMF, the gene 
Bim (Bcl2l11) and Bid were also found downregulated. 
 The RNA-Seq analysis was complete with the addition of three expression 
libraries of lactating JAK1-knockout mammary glands. The remarkable precision of RNA-
Seq allowed us to view the expression of individual exons of genes, notably, Jak1. In all 
sets of tissue, in the sample comparison of experimental and control groups during 
lactation and involution, we were able to precisely identify the excision of the second 
coding exon in the experimental tissue (Fig. 3.5, top). We noted an increase in Jak1 
expression levels throughout the involution tissues, which correlates to the increased 
JAK1 protein levels tested at the same developmental window (Fig. 3.1A). JAK1 had no 
effect on JAK2/STAT5-responsive genes, such as beta-casein (Csn2) (Fig.3.5, middle). 
Observing the STAT3 target genes such as Cd14 and c-Fos, their transcriptional levels 
were remarkable decreased, as were the newly identified proapoptotic genes, Bmf and 
Bim. Although both genes displayed over 2-fold deregulated expression, Bmf had 4-fold 
higher expression profile in wild-type tissue overall (Fig. 3.5, lower). Similar to the 
previous report of the upregulation of Pik3r1, the p50/55 isoforms of the 
phosphatidylinositol 3-kinase (PI3 kinase), we found that Runx1 was selectively 
expressed from an intronic promoter that encodes the shorter isoform 3. This finding 
exemplifies the fidelity of RNA-Seq technology but also demonstrates the importance of 
using appropriate antibodies that recognize various isoforms at the protein level. 
 Confirmation of the newly identified JAK1 targets was done by immunoblot, 
Supporting the earlier findings that JAK1 had no effect on the activation of STAT5 during 
lactation, phosphorylated STAT5 was consistent in wild-type and knockout lactation 
tissue (Fig. 3.6A). Analysis of STAT3 confirmed upregulation of active STAT3 at the 
onset of involution throughout control samples, but was significantly reduced in the 
involution tissue of the knockout. The targets identified by RNA-Seq, RUNX1, BMF, BIM, 
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and WFDC5 also demonstrated reduced protein expression. Both RUNX1 and c-FOS 
have known expression in the hematopoietic system and immunostaining of these 
targets on histological sections of control and JAK1-deficient tissues demonstrate that 
they are indeed upregulated during involution, but their expression depends on JAK1 
(Fig. 3.6B and C). 
 
BMF and BIM are downstream targets of JAK1, and their combined deficiency 
phenocopies an impairment of mammary gland remodeling similar to JAK1-
deficient mice. 
 The analysis of the mRNA profiles of lactating and involuting mammary tissues 
show that several genes of the Bcl2 family members display notable changes in their 
expression. We observed not only more than a 2-fold upregulation of Bax, Bcl-x (Bcl2l1), 
Bmf, Bim (Bcl2l11), and Bid, but a 3 and 7-fold upregulation of Bbc3 (Puma) and Bik 
(Fig. 3.4). A more than 2-fold downregulation of prosurvial factor Bcl-w (Bcl2l2) was also 
seen during involution (not shown). The most significantly downregulated Bcl2 family 
member was Bmf, along with Bim. In order to identify whether these two genes were 
preferentially bound by either STAT5 or STAT3, we performed preliminary analysis of 
the ChIP-Seq data sets from female glands during mid-pregnancy, a time point that 
represents when all STAT proteins that are expressed in the gland are active at various 
levels (Fig. 3.7). Socs2 and Socs3 served as preferential binding controls for STAT5 and 
STAT3, respectively. We observed a strong preference for STAT3 binding sites near 
Osmr, Bcl3, and Stat3, which is depicted in the histograms (Fig. 3.7). STAT3 was also 
showed enrichment in binding near Bmf and Bim. To quantify the binding of STAT3 of 
both Bmf and Bim, during the development phases of lactation and involution, we 
performed ChIP followed by quantitative reverse transcription-PCR (qRT-PCR) for 
canonical gamma interferon activation sites (GAS). We found that STAT3 occupied GAS 
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sequences near transcriptional start sites of both genes, and that the binding of DNA 
was greatly increased during involution (Fig. 3.8). The combined results of the ChIP-Seq 
and qRT-PCR data further suggest that STAT3 promotes the transcription of these pro-
apoptotic family members during involution. 
 As Bmf and Bim appear to be downstream targets of JAK1/STAT3 signaling we 
anticipated that a functional loss of Bmf alone or in combination with Bim may 
phenocopy the delayed involution signature of the JAK1 conditional knockout mice. To 
answer this question we examined the histology of lactating and involuting glands of 
BMF- and BIM-single-knockout mice. Similar to the JAK1-knockout phenotype, the 
functional loss of either protein did not affect lactating tissue, although, we saw a delay 
in the remodeling process in both mutant tissue, with the observation being more 
pronounced in the BMF-deficient glands (Fig. 3.9). These phenotypic observations of the 
BH3-only family members provide evidence for their functional role for initiation 
apoptosis in differentiated mammary epithelial cells. Based on our data comparing 
lactation tissue to involution, where the two proteins are upregulated during involution in 
tandem, we hypothesized that they might act synergistically during the remodeling 
phase. Experimentally, we addressed this question by transplanting BMF/BIM-double-
knockout tissue into the cleared mammary fat pad of wild-type recipient female mice. 
Tissue engraftment was successful and following ductal outgrowth after 12 weeks post-
transplantation, recipient mice were bred and mammary glands were collected 
immediately following birth of offspring (Fig. 3.10, postpartum). Similar to a deficiency in 
a single gene, the double knockout tissue was indistinguishable from that of wild-type 
glands during lactation. However, we saw a striking delay in the remodeling process of 
the double-knout tissue (Fig. 3.10, involution). Histological analysis of active STAT3 in 
BIM- and BMF-single and double knockout mice demonstrate a clear and strong nuclear 
stain for the transcription factor, and was comparable to the wild-type involution tissue 
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(Fig. 3.10). Because the recipient mice are wild-type for JAK1, it is evident that these 
proteins act in a cell-autonomous manner. These results suggest that both proapoptotic 
family members have a significant role in the remodeling process and biologically 






Fig. 3.1. JAK1 is essential for the activation of STAT1, STAT3, and STAT6 in 
embryonic fibroblasts and mammary epithelial cells. (A) Immunoblot analysis of the 
expression of JAK1 and tyrosine phosphorylation of STAT1, STAT3, STAT5 and STAT6 
during mammary gland development. (P numbers indicate day of pregnancy; L7, 
lactation day 7; I2, involution day 2). The individual panels represent immunoblots of 
tissues from different mice. (B) Expression of JAK1 and JAK2 as well as steady-state 
activation of STAT1 and STAT3 in primary mouse embryonic fibroblasts (MEFs) from 
heterozygous and homozygous JAK1-knockout embryos which were generated through 
germ line deletion of the floxed locus (Jak1=/- [+/-] and Jak1-/- [-/-], respectively) as well 
as MEFs from wild-type controls (Jak1=/= [+/+]). (C) IP/Western blot analysis of STAT5 
and STAT6 in GH- and IL-4-treated wild-type and JAK1-knockout MEFs. (D) 
Immunohistochemical staining of active STAT5 and STAT3 on mammary tissue sections 
from a JAK1 conditional knockout mouse (MMTV-Cre Jak1flox.flox [MCre Jak1fl/fl] and a 
littermate wild-type control (Jak1flos/flox[Jak1fl/fl] at day 14.5 of gestation. The slides were 
counterstained with hematoxylin. Bar, 50 μm. (E) Western blot analysis of 
phosphorylated STAT1, STAT3, and STAT6 in explanted mammary epithelial organoids 
from mice with mammary gland-specific JAK1 knockout and their wild-type controls with 






Fig. 3.2. The biologically relevant function of JAK1 is restricted to the remodeling 
phase. (A) (Top) Fluorescence images using the GFP-based reporter for recombination 
in wild-type (left) (MMTV-Cre Jak1flox/+ CAG-LSL-GFP) and JAK1-knockout (right) 
(MMTV-Cre Jak1flox/flox CAG-LSL-GFP) nulliparous mammary glands. Whole mount 
images of control and knockout mammary glands fixed and stained by carmine alum, 
display similar ductal architecture (Lower). (B) H&E-staining of sectioned mammary 
glands from control and JAK1-deficient experimental females at the timepoints of 
lactation (left) and two involution timepoints (right). Bars,100 μm. (C) Whole mount 
analysis comparing the MMTV-Cre deletion of Jak1, and the WAP-Cre-mediated 
excision of Jak1, along with wild-type controls, each as involution day 5. Bars, 2 mm. LN, 
lymph node.  
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Fig. 3.3.  
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Fig. 3.3. Analysis of STAT activation in the mammary gland and embryonic 
fibroblasts in response to cytokines OSM and LIF. (A) Immunostaining of tyrosine 
phosphorylated STAT3 and STAT5 in the wild-type and conditional JAK1-knockout 
mouse mammary gland during lactation and involution. Bar, 50 μm. (B) Western blot 
analysis of tyrosine-phosphorylated STAT1 and STAT3 in embryonic fibroblasts wild-
type, heterozygous, or homozygous-deficient in Jak1, in response in LIF and OSM 
treatment. (C) Nulliparous mammary glands from wild-type and JAK1-knockout females 







Fig. 3.4. Comparison of the gene expression between normal lactation and 
involuting glands, and identification of genes deregulated in a JAK1-dependent 
manner during remodeling. (A) Gene set enrichment plots with heat maps of genes 
that are selectively upregulated during the second day of involution compared to their 
status in lactation. (B) Heat maps of selected genes that are upregulated during 
remodeling but experience a 2-fold or more downregulation in the JAK1-deficient gland. 






Fig. 3.5. Janus kinase 1 is necessary for the expression of STAT3 target genes 
and newly-identified JAK1-dependent genes. The individual histograms depicting the 
RNA-Seq data from wild-type and JAK1-knockout glands during lactation and involution, 
depict the expression levels of the identified genes as well as their exon usage. (Upper) 
the box highlighting the exon 2 of Jak1 indicates the deletion of the exon in the knockout 
samples. (Middle) the milk protein gene Csn2, serves a control for a STAT5-responsive 
target that is downregulated during involution. Cd14 and Pik3r1 provide controls for 
STAT3 targets known to increase during involution under normal conditions, and whose 
expression is reverted in the knockout glands. C-Fos, Bmf, Bim, and Runx1 are newly 





Fig. 3.6. Confirmation of target gene protein expression in wild type tissue and 
JAK1-deficient tissue by Western blot and immunofluorescent staining. (A) 
Western blot analysis of control and knockout tissue during lactation and involution 
depict a decrease in the target proteins RUNX1, BMF, BIM, WFDC5. (B and C) 
Immunofluorescence of the target genes RUNX1 and c-FOS on lactation day 9 tissue 
and involution day 2, with E-cadherin (CDH1) and DAPI served as counterstain. Bars, 50 
um. (C) Inset panel demonstrates closer view of tissue lacking c-FOS expression  
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Fig. 3.7.  
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Fig. 3.7. STAT3 and STAT5 demonstrate various binding affinities for downstream 
target genes. The individual panels display the histogram of ChIP-Seq data sets for 
select target genes, and portrays the transcription factor binding in midpregnant glands. 
Socs2 and Socs3 serve as binding controls for STAT5 and STAT3, respectively. STAT3 
has prominent binding near sites of Osmr, Bcl3, and Stat3 itself. The newly identified 
targets, Bmf and Bim display higher affinity for STAT3 binding in proximity to these loci 





Fig. 3.8. qRT-PCR from ChIP by STAT3 and STAT5 demonstrates the binding of 
STAT3 and STAT5 to target genes during lactation and involution. Schematic 
outline of the location of canonical STAT binding sites near or within the genes encoding 
for BH3-only proteins BMF (A) and BIM (B). Boxes indicate the location of exons, and 
numbers refer to exon number. Bar graphs demonstrate results of quantitative real-time 
PCR from DNA isolated by ChIP in lactation day 7 and involution day 2 mammary tissue 
with antibodies directed against STAT3, STAT5, and IgG control. Primer sets used to 
amplify select regions surrounding STAT-binding sites are specific for sequences 
located within the 5’ intragenic regions of BMF and Bim. Values were normalized against 




Fig. 3.9.  
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Fig. 3.9. The remodeling events are delayed in mice that genetically lack BMF or 
BIM. The H&E staining was performed on tissue collected from mice during lactation and 
involution from mice wild-type for both genes (BMF+/+ Bim+/+), lacking only BMF (Bmf -/- 






Fig.3.10. Double knockout mice for BMF and BIM display impaired remodeling. 
Whole mount analysis reveals that while wild-type mice progress through normal 
involution (left panel) the recipient mice of the double knockout tissue have a notable 
delay in the involution process (middle, right). Tissue was collected after birth of 
offspring and four days after weaning. Immunohistochemical staining of the wild-type 
and double knockout tissue for phosphor-tyrosine STAT3 indicate strong nuclear 




The biologically essential functions of JAK1 are restricted to the events of 
postlactational remodeling of the mammary gland. 
 Through the extensive characterization of STAT proteins and their activity in the 
JAK1 conditional knockout mouse model, it was shown that JAK1 contributed to the 
cytokine-induced tyrosine phosphorylation of STAT1, STAT3, and STAT6, not only by 
cell culture in embryonic fibroblasts but in the developing female mammary gland. 
Although JAK1 was responsible for the activation of three STAT family members, the 
phenotypic consequence for the lack of JAK1 in a developing gland was largely 
restricted to the postlactational remodeling phase where there was a failure of the gland 
to respond to the acute rise in inflammatory cytokines. This delay in remodeling 
resembles the phenotype of STAT3-deficient glands, as well as models that lack gp130 
or IL-6 [49, 67]. The loss in activation of STAT1 and STAT6 within the mammary 
epithelium did not impede growth or development of the gland. Previous reports are 
indicate that STAT1 is dispensable for ductal elongation and alveologenesis and that the 
role of STAT1 in mediating optimal ductal branching is dependent on active STAT1 in 
the stroma [54].  A STAT6 deficiency has been shown to impair mammary alveolar 
development during early pregnancy, a phenotype that was observed to be repaired 
during later stages of gestation with no defects noted during lactation. The rebound of 
the gland during stages in pregnancy could be due to a paracrine effect of STAT6 in the 
stroma inducing mammary epithelial proliferation [55]. This may explain why a JAK1-
deficiency in the mammary gland does not phenotypically compare with a STAT6-
knockout model. 
 
The Janus kinase 1 and 2 may have nonredundant roles in the activation of STAT 
proteins during mammary gland development. 
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 Previous work investigating JAK2 in the mammary gland describes the kinase to 
specifically activate STAT5 in the mammary gland compartment, in response to PRL 
signaling. The mammary-specific deletion of JAK2 resulted in the impaired development 
and growth of alveolar cells, and no compensation by another kinase or downstream 
mediators of the JAK2/STAT5 pathway was observed to rescue the phenotype [60]. 
Strikingly similar, the loss of JAK1 in the developing mammary gland had no effect on 
the activity of STAT5, and in the involution events, and the loss of response to 
inflammatory cytokine signaling, no other kinase was able to effectively compensate for 
the genetic lack of JAK1 and subsequent STAT3 activation. The collective findings of 
each in each of these studies indicate that JAK1 or JAK2 is not able to compensate for 
the loss of the other to activate STAT5 or STAT3 in the same cell type, in response to 
ligand-receptor signaling (Fig. 3.11). Observations built from the biological and molecular 
phenotype support the idea that there may be no functional overlap between the kinases 
during normal gland development. The impact of this premise could be far-reaching as 
there are man reports that state JAK1 and JAK2 are capable of phosphorylating STAT3, 
in response to inflammatory cytokine signaling in vitro. It has been observed in initial 
studies that JAK1 mediates IL-6 signaling [94-97], yet current work has displayed JAK2 
as the key mediator for STAT3 activation in the disease setting [98-101]. This could 
largely be due to the use of pharmacological inhibitors that are labeled as “JAK2 
inhibitors”, when in they actually may inhibit both JAK1 and JAK2 with near similar 
kinetics [102]. A strong argument again the role of JAK2 activating STAT3 is displayed in 
recent work, where a genetic deletion of JAK2 in mammary cancers still display 
constitutive STAT3 activation [80]. Furthermore, STAT3 signaling in malignancies has 
been shown to depend on IL-6 autocrine signaling [103-106], initiated by receptor 
tyrosine kinases. We have demonstrated that JAK1 is essential for gp130-mediated 
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signaling, and that this kinase and not JAK2 may be crucial for targeting the persistent 
activation of STAT3 in disease.  
 
JAK1 is a crucial mediator of IL-6-class inflammatory cytokine signaling and 
activating downstream cell death complexes in differentiated mammary 
epithelium. 
 The collective findings provide rational that JAK1 maintains a crucial function 
during the involution phase of mammary gland development. The expression levels of 
JAK1 were observed to rise during the involution time points by protein analysis and 
validated at the transcriptional level by RNA-Seq. The deletion of this kinase closely 
mirrored the biological consequences seen in STAT3-, gp130-, or IL-6-deficient mice 
[36, 49, 67]. The functional loss of JAK1 uncoupled inflammatory cytokine signals from 
their downstream effector STAT3, which led to a deregulated expression of STAT3 
target genes during this biology time point. The genome-wide investigation of genes 
selectively upregulated druing involution in a JAK1-dependant manner revealed known 
STAT3 targets such as Osmr, Cd14, and STAT3 itself, as well as targets such as c-Fos, 
a proto-oncogene known for its regulation in tissue remodeling by regulation of 
metalloproteinases [107-109]. Other targets included Tpl2 (Map3k8), and death receptor 
6 (Tnfsf21), although their functions have not been explored. The function of JAK1 in 
coupling cytokine signaling to crucial mediators of mitochondria-associated cell death 
machinery was found in its regulation of the BH3-only protein BMF and BIM. Single 
knockouts of each BMF and BIM confirm their role in aiding in remodeling, and 
synergistically, a double knockout of both proteins dramatically delays remodeling [110]. 
This phenotype corresponds to the knockout JAK1, where upending JAK1 deregulated 
both BMF and BIM in the mammary epithelium. Corroborating data from the RNA-Seq 
analysis and qRT-PCR demonstrate that STAT3 binds in close proximity to these genes. 
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Although, the STAT3-deficient knockout did not show similar deregulation, suggesting 
that other transcription factors whose expression level depend on JAK1 also contribute 
to the regulation of Bmf and Bim, or that STAT5 may function a suppressor or Bim [111]. 
Although, the nuclear localization of active STAT3 is unchanged from wild-type mice to 
knockouts of BMF and BIM, which supports that these two factors function downstream 
of STAT3. While the lysosome-mediated pathway, driven by STAT3, an alternative 
model for remodeling in the mammary gland [111], its activity was not able to offset the 
inhibited canonical apoptotic pathway. The conditional knockout model of JAK1 in the 
mammary gland led to impaired remodeling and downstream targets of JAK1/STAT3 
signaling were verified on a genome-wide scale and confirmed at the protein level and 
validated in genetic in vivo knockouts, demonstrating that this kinase is essential for 





Fig. 3.11. JAK1 and JAK2 display nonredundant functions and activate 
specific STAT proteins in mammary epithelial cells. JAK2 mediates the signal 
of PRL to activate STAT5 during lactation. The switch to involution requires JAK1 
to activate STAT3 downstream of inflammatory cytokines OSM and LIF during 
involution. 
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The results of the previous chapter clearly illustrate that JAK1 is the essential 
mediator for the inflammatory signaling in the mammary gland [86]. The Cre/lox system, 
under control of the MMTV promoter, specified the deletion of Jak1 to the mammary 
gland and avoided perinatal lethality [20].  As the MMTV promoter is active during 
development, the mice were monitored from birth to pregnancy and through involution. 
Most striking was the phenotype of female mice undergoing remodeling. While a 
mammary-specific Jak1 deletion had no effect on mammary gland development prior to 
or during pregnancy, involution was strongly delayed, evidenced in the sustained 
maintenance of the mammary epithelium, failure of matrix remodeling, and absence of 
activated STAT3. This phenocopies the STAT3 and LIF-deficient models, and highlights 
that JAK1 is crucial for mediating the effects of IL-6 class cytokines. 
Surprisingly, JAK1 not only contributed to the activation of STAT3, but also to the 
phosphorylation of STAT1 and STAT6. While these two transcription factors are active in 
the developing mammary gland and early stages of pregnancy, development of JAK1-
deficient mammary glands were indistinguishable from wildtype. This may be attributed 
to knockout models of STAT1 and STAT6 demonstrating their effects in the stroma [54, 
55], 
The previous studies of JAK2 along with the results in Chapter 3 indicate that the 
Janus kinases may have non-redundant roles in STAT activation. Evidence is seen in 
data of JAK2 deletion leading to inactivation of STAT5 in the mammary gland, with no 
compensation by another kinase [60, 112]. JAK1-deficient mammary epithelial cells had 
no effect on STAT5 activation downstream of PRL signaling but failed to phosphorylate 
STAT3. This signifies that the two kinases may not have functional overlap during 
mammary gland development. Understanding the role of the Janus kinases exemplifies 
the importance of targeting kinases according to function and STAT activation. 
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Across several types of cancer, such as head and neck squamous cell 
carcinoma, melanoma, and breast cancer; STAT3 is demonstrated to be a contributor to 
malignant disease [70, 104, 113]. The function of STAT3 appears to support migration 
[35]. In breast cancer, 20-30% of cases exhibit amplification of HER2/Neu, which 
contributes to a growth regulatory network that sees a high prevalence of active STAT3 
driving aggressive disease and contributing to metastasis [114-116]. 
Comparing normal mammary gland development to breast cancer, STAT3 
appears to have opposing functions. During postlactational remodeling, STAT3 is 
essential for cellular breakdown and apoptosis, compared to its described role in breast 
cancer where it drives growth and aggressive disease. Although in development STAT3 
was described as necessary for initiating apoptosis during the remodeling process, this 
is one facet of the involution phase. Several other important components are occurring 
as well, such as upregulation of matrix metalloproteinases to degrade the underlying 
matrix and allow the cells to detach from the basement membrane. In this way, STAT3 
may be preferentially active in established disease to promote aggressive phenotypes.  
We proposed to address the contribution of JAK1 to activating STAT3 in the 
context of tumor formation and disease progression by generating in vivo cohorts that 
express the neu oncogene in a mammary-specific manner, while the experimental group 
also had Jak1fl/fl locus deleted prior to disease formation using the mammary-directed 
Cre recombinase. If JAK1 maintains nonredundant activation for STAT3, as shown in 
normal development profile, it may display biological relevance in mediating the 
migration properties associated with STAT3. 
 
Results 
JAK1-deficient MMTV-neu tumor model displays absence of metastatic disease 
while tumor onset remains unaffected 
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Janus kinase 1 is necessary for the activation of STAT3 in immortalized 
embryonic fibroblasts and is the key mediator of inflammatory cytokine signaling in the 
mammary gland during the postlactional remodeling events during development, 
coupling the IL-6-class ligands to downstream effectors through STAT3 [86]. The high 
prevalence of tyrosine phosphorylated STAT3 in aggressive cancers, and STAT3’s 
association with driving proliferative disease, led us to test if a JAK1-deficiency in the 
mammary gland-specific ErbB2-driven tumor model would experience differential tumor 
onset or malignant progression. In order to study the tumorgenesis profile, we generated 
a mouse model that overexpressed the ErbB2 gene specifically in the mammary gland 
concurrent with a mammary-specific deletion of Jak1 in the same epithelium, and also 
tracked with a GFP reporter (MMTV-neu MMT-Cre Jak1 fl/fl CAG-LSL-GFP). As the 
MMTV promoter is expressed within the luminal and myoepithelial compartments during 
development, both oncogene expression and the deletion of the floxed alleles occur 
within the same cell. Latency of MMTV-neu-driven mammary tumors is approximately 
220 days, and MMTV expression occurs well before puberty, thus producing Jak1-
deficient cells prior to tumor onset. The littermate controls lacked Cre recombinase, 
preserving the Jak1fl/fl , rendering it wild-type (MMTV-neu Jak1 fl/fl CAG-LSL-GFP). Both 
experimental and control female mice were bred twice to induce proliferation and 
expansion of cells in the mammary gland, and monitored for mammary lesions by 
palpation biweekly for up to 12 months. Histological observation of control and knockout 
glands depicted normal patterning of ductal branching and alveologenesis. Also the 
absence of negative selection in Jak1-deficient cells was noted by observing the Cre-
mediated expression of the GFP reporter in the mammary glands (Fig. 4.1A). Analysis of 
39 tumor-bearing control females and 14 JAK1-deficient mice revealed that the tumor 
onset did not vary statistically between the two groups (Fig. 4.1B). At the time of 
necropsy, the resected tumors were analyzed for GFP, if induced by Cre recombinase, 
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and analyzed as well for evidence of metastatic lesions in the lung, as the MMTV-neu 
model is well-documented to readily metastasize to the lung [114]. Consistent with these 
reports, the control females demonstrated lesions to the lung, identified by GFP, 
interestingly, the JAK1-deficient females had no comparable lesions in pulmonary tissue 
(Fig. 4.1C). This observation raises a critical question on the need for JAK1 during tumor 
initiation versus disease progression. 
 
Janus kinase 1 is necessary for the activation of STAT1, STAT3, and STAT6 in 
mammary tumor epithelium in vivo and tumor cells in vitro. 
To assess if JAK1 maintained regulation and activation of STAT3 in tumors, 
Western blot was performed on control MMTV-neu mammary tumor lysate alongside 
tumors from mice deficient JAK1. The results demonstrate that even in the disease 
setting, an absence of JAK1 correlated with a deceased activation of STAT3, along with 
tyrosine-activation of STAT1 (Fig. 4.2A). The activation of STAT6 was not evident in the 
control tumors, when compared with cells stimulated with IL-4 (Fig. 4.2A). 
Immunohistochemistry was performed and staining displayed strong nuclear staining of 
activated STAT3 within control tumors; interestingly, the strongest signal was produced 
along the leading edge of the tumors and near blood vessels. In comparison tumors 
deficient in JAK1 had a marked decrease of active STAT3 within the tumor tissue, yet 
retained activity in the stroma (Fig.4.2B). When immunostaining was performed for 
localizing phosphorylated STAT1, low levels were seen within the tumor, consistent with 
the decrease in protein expression by Western blot (Fig.4.2B).  
In order to verify the tumor intrinsic characteristics with a lack of JAK1, isogenic 
cell lines were derived from control mice harboring the Jak1fl/fl alleles, deleting Jak1 by 
viral mediated Cre recombinase. The confirmed excision of JAK1 by immunoblot was 
followed by an inhibition of STAT3 activity (Fig. 4.2C). The deletion of JAK1 also led to a 
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significant decrease in active STAT1. STAT6 demonstrated the same lack of 
phosphorylation in the knockout cell lines when stimulated with IL-4, as the cells did not 
express active STAT6 at steady state levels (Fig. 4.2C). The Jak1-deficient cells had no 
growth deficiencies while in culture, consistent with reports from STAT3-deficient 
epithelial cells [35]. Although curiously, their phenotype changed from a stretched 
cobblestone, spindle appearance, to a compact epithelial morphology in the absence of 
JAK1 (Fig.4.2D). 
 
A lack of JAK1 drastically decreases tumor growth of transformed cells in vivo 
and reduces incidence of metastatic disease. 
While tumor initiation and tumor progression are commonly associated as the 
same events, they are two very different biological processes, requiring distinct 
mechanisms for initial transformation of cells to sustained proliferation and migration 
capacity. To address the function of JAK1 in mediating progression of disease, the 
isogenic cell lines were treated by lentiviral infection, incorporating a luciferase reporter 
construct for in vivo bioluminescence to monitor for growth and distant disease. Cells 
were transplanted into the number 4 mammary glands of recipient female mice. 15 mice 
per group were transplanted with 1x106 tumor cells per gland (total of 30 transplants per 
cell line were performed) and monitored weekly for growth using calipers and 
bioluminescence. Over the course of 8 weeks, the wild-type cells engrafted and 
proliferated robustly, indicating that they maintained their neoplastic properties, strikingly 
the isogenic-matched JAK1-deficient cells appeared to have engrafted, as indicated by 
the continued bioluminescence assays, but demonstrated a lack of proliferation as 
compared to the wild-type cells within the same amount of time (Fig. 4.3A, B). At 
necropsy, the mice transplanted with the MMTV-neu tumor cells carried metastasis 
within the lung, along with two mice presenting with metastasis in the liver and pancreas. 
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Assessment of the lungs and pancreas of the mice transplanted with the JAK1-deficient 
cells found no evidence of metastatic disease (Fig.4.3C). Verifying that transplant had no 
effect on the activation of STAT3, the tumors were subjected to immunblot, confirming 
the sustained STAT3 phosphorylation in wild-type cells and a maintained decrease in 
JAK1-deficient transplanted cells (Fig.4.3D). Histological analysis of the transplanted 
tumors of both wild type and knockout tumors demonstrated an invasive phenotype seen 
in the wild-type tumors, as they lacked defined borders, while the JAK1-deficient tumors 
maintained a compact phenotype. When the lungs were surveyed for metastatic 
disease, distant disease was evident, and at time multifocal, while lungs of the mice 
transplanted with JAK1-null cells remained free of disease (Fig. 4.3E). To ensure that 
this was not an artifact of cell culture, minced tumor fragments from control and JAK1-
deficient tumors were transplanted into the number 4 glands of recipient female mice 
(mice each cohort, total of 16 transplants performed) and monitored for growth. The 
growth patterns mirrored that of the cell line transplants, although the knockout tissue 
exhibited growth several weeks earlier, possible due to a selection of wild type or 
unrecombined Jak1 floxed allelles. When the tumors were analyzed for active STAT3, 
the control tumors as well as the resulting lung metastasis (Fig. 4.3G) were positive for 
phosphorylated STAT3, indicating that active STAT3 may be important not only in the 
primary tumor but also disease progression, and critical for the metastatic process and 
propagation at the secondary site. The JAK1-deficient tumors continued to display very 
little activation of STAT3 within the tumor, although the stroma contained persistent 
STAT3 phosphorylation (Fig. 4.3G). While the signaling events necessary for tumor 
formation seem independent of JAK1, these results evidence JAK1 as an integral 
mediator of disease progression. 
 
Signaling through JAK1 is required for cancer cell migration  
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Prompted by the behavior of the transplanted cells, we performed in vitro assays 
to verify migration characteristics. The trans-well migration assay demonstrated that the 
migration patterns of the tumor cells were inhibited by a JAK1 deletion, reducing the 
number of cells that migrated by nearly fifty percent and paralleling the same behavior 
seen in vivo (Fig.4.4A). The results are consistent with the previous reports in STAT3-
deficient cells, that while the cell growth in vitro remained unchanged, migration was 
impaired, suggesting that STAT3 acts in mechanisms associated with motility [35]. The 
extent to which the JAK1-deficient cells lacked growth compared to the wild-type tumor 
cells is reminiscent of data and phenotypes that depict the loss of tumor-initiating cells 
[117, 118]. Performing a tumorsphere assay, we identified whether cells have the 
required biological properties to generate tumors under low-attachment conditions. 
Permitting the cells to grow for a duration of seven days, the wild-type cells readily 
formed multiple spheres, meanwhile the tumor cells lacking JAK1 failed to proliferate 
under the same conditions, synergizing with their behavior in vivo (Fig.4.4B). A marker of 
tumor-initiating capability, specifically within the ErbB2-driven tumor population was 
found to be CD61 [119], when we analyzed our control cells against the JAK1-deficient 
cells, we observed a shift in the expression of the surface marker (Fig. 4.4C). The data 
suggest that more than STAT3 is deregulated with the deficiency of JAK1. 
 
Identifying target genes downstream of JAK1 signaling mediating tumor 
progression. 
 To identify potential JAK1-dependent mechanisms that contribute to tumor 
progression, we prepared cell lines for whole genome RNA-Seq analysis followed by 
Gene Set Enrichment Analysis. Initially, five control tumor cell lines were compared 
against four JAK1-deficient cell lines, validating the loss of JAK1 in a larger sample size. 
241 genes displayed a significant deregulation by 2.5-fold change or greater, 185 genes 
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were downregulated in the absence of JAK1 and 56 had increased expression in JAK1-
deficient cells, represented by a heat map of the top deregulated genes (Fig. 4.5A).  
Deriving genes directly targeted by the JAK1/STAT3 signaling axis, analysis was 
performed comparing the two isogenic cell lines. The top genes expressing the greatest 
fold change by deregulation in the knockout cell lines are illustrated in Fig. 4.5B, the 
focus for the following experiments expound on the genes with lower expression in the 
JAK1-deficient cells, capitalizing on the function of STAT3 as a transcription factor. The 
reversal of expression (lower Fig. 4.5B) may be a secondary result of JAK1 deletion. 
Genes set enrichment analysis was performed on the isogenic cell lines, to identify 
genes and functional pathways that may apply to biological processes. The deletion of 
JAK1 led to the deregulation of downstream target genes associated with JAK/STAT 
signaling, focal adhesion, and toll like receptor signaling (Fig. 4.5C). Specifically, 
potential targets, such as Fos, Map3k8, and MyD88 were found downregulated in a 
JAK1-dependent manner. The tumor susceptibility gene, Tpl2 (Map3k8) activates 
pathways such as the MAP kinase and NF-κB, and has demonstrated transforming 
capabilities [120], along with MyD88, whose expression integrates into the toll-like 
receptor pathway to promote metastasis and proliferation [121]. Reinstating expression 
of these targets in a JAK1-deficient background would identify their contribution to 
disease progression. 
 Next, we validated the expression of putative JAK1 targets. A sizeable 
downregulation was seen in the JAK1-deficient cells in the expression of the oncogene 
Fos, as well as a known STAT3 binding target, Socs3. The Jak1 locus depicted the loss 
of exon 2, supporting the fidelity of the sequencing and the identification of downstream 
targets (Fig. 4.6A). Testing the expression and localization of select target genes on 
tumor sections demonstrated a loss of platelet-derived growth factor alpha (PDGFA), the 
STAT3 target OSMR, a reduction in CD14, large reduction in expression of BCL3 and c-
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FOS (Fig.4.6B). Immunoblot analysis confirmed the downregulation of the select targets 
in the Jak1-knockout cell lines (Fig. 4.6C). 
 
Re-expression of downstream JAK1-signaling target FOS partially rescues 
growth-deficient phenotype 
 Expression of Fos was dramatically deregulated in the JAK1-deficient cells, as 
identified by the RNA-Seq results (Fig. 4.6A), and perpetuated in the analysis by 
immunostaining tumors wild type and deficient in JAK1 (Fig. 4.7A). Protein expression 
was also concurrent in the cell line analysis by Western blot (Fig. 4.6C). Curious, we 
postulated if this protein could rescue the growth-deficiency seen in the Jak1-knockout 
tumors. To test this hypothesis, we generated a lentiviral construct to reinstate 
expression of FOS in JAK1-deficient tumor cells. The cells were established and 1x106 
cells transplanted into the number 4 mammary glands of recipient Athymic nude mice 
and monitored for growth weekly. Tumors began to proliferate noticeably at week 6, 
where the tumor size was considerably larger that the JAK1-knockout cells (Fig.4.7). The 
partial rescue in growth of the FOS-expressing JAK1-defcient cells did not completely 
mirror the growth patterns of the Jak1+/+ cells suggesting that complimentary factors 
must be associated with growth in a JAK1-dependent manner. Further rescue studies 
will describe additional proteins that can be tested in the same design, identifying and 
validating critical effectors of JAK1 signaling. These studies may identify potent JAK1-
dependent targets necessary for in vivo tumor growth along with identifying genes 











Fig. 4.1. Characterizing a deletion of Jak1 during mammary tumor initiation and 
progression. The GFP-based reporter identifies Cre recombinase activity. The deletion 
of Jak1 (knockout, right) did not affect growth of the duct or the alveolar branching as 
viewed by Carmine alum staining (A). Tumor onset was showed no statistical difference 
between the control and experimental groups (B). Mammary tumors displayed GFP-







Fig.4.2. JAK1-deficient tumors display a lack of active STAT3 and STAT1 (A). The 
whole tumors lysates also have active STAT1, which is absent in the knockout tumors. 
STAT6 is not active within the tumors, when compared to cells stimulated with IL-4. 
Immunohistochemistry demonstrates the localization of active STAT3 to the nucleus of 
tumor cells, with staining evident tumors (T) as well as the surrounding stroma (S), 
compared to a notable decrease to near absence of STAT3 staining in the tumor, but still 
seen in the stroma. Bar,100 μm (B). Tyrosine-phosphorylated STAT1 is evident within 
the control tumors, while decreased within JAK1-knockout tissue. Isogenic cell lines 
were generated and verified for the presence of JAK1 in wild type cells (WT) and 
deletion for Jak1 in the knockout cell lines (KO). JAK1 is shown to contribute to the 
activation of STAT6 in the presence of IL-4 stimulation, as well as STAT1 at stead-state 
conditions (C). Morphologically, the Jak1 wild type cells appear stretched, while a 







Fig.4.3. In vivo growth of transplanted JAK1-deficient cells results in a severe 
decrease in growth and occurrence of metastasis. To address the implications of a 
JAK1-deficiency in established tumor cells, the isogenic cell lines were infected with a 
luciferase construct to allow for bioluminescence tracking (A). The transplanted JAK1-
deficient cells displayed a large inhibition in growth compared to the JAK1 wild type cells 
(A). The growth curve demonstrates the rapid growth of the control cells versus the 
JAK1-deficient cells (B). The wild type mice displayed multiple lung lesions, as well as 
metastasis to the liver and pancreas, while metastatic disease was absent in the Jak1-
knockout recipient mice (C). The transplanted cell line tumors were analyzed for STAT3 
activity, and the knockout retained the muted activation of tyrosine-phosphorylated 
STAT3 (D). Histology of the control mammary tumors and lung tissue presenting 
metastasis (M), compared to the JAK1-knockout cell transplant mice display the 
engrafted and formed tumor and lung tissue, bar 100 μm (E). Verifying that the previous 
results are not an artifact of cell culture, whole tumors, JAK1 wild type, and JAK1-
deficient were minced and transplanted into recipient Athymic nude female mice. The 
growth curve resulted in the similar trajectory of the transplanted cell lines (F). Analysis 
of the transplanted tumor fragments depict the morphology by H&E of the wild type 
tumors and lung tissue displaying metastatic disease (M), as well a tumor tissue from the 
Jak1-deficient tumors. Control and knockout tissue was stained for phosphorylated 
STAT3 (red), and luminal cell marker, CK* (green), demonstrating high activity with the 
control tumor as well as the lung metastasis, while this was absent in the transplanted 








Fig.4.4. The deletion of Jak1 results in decreased migration, tumorsphere 
formation, and reduction in tumor-initiating cell marker CD61. The migratory 
capacity of the wild-type cells (Jak1+/+) and JAK1-deficient cells (Jak1-/-) was tested by 
trans-well assay (bar= 1 mm), decreasing migration nearly 50%, P= <0.05 (A). The cells 
were then analyzed for tumor-forming capability by tumorsphere-forming assay. Wild 
type cells (Jak1-/-) readily formed tumorspheres, while in the knockout cells (Jak1+/+), this 
morphology was greatly reduced (B). Cells were tested for the cell surface marker 
expression of CD61, a marker implicated in tumor-initiating cells and was found to be 







Fig.4.5. Whole genome RNA-Sequencing revealed the JAK/STAT, toll-like receptor, 
focal adhesion, and ECM receptor pathways to be deregulated in a JAK1-
dependent manner. Five JAK1 wild type cell lines (Jak1+/+), and four JAK1-deficient cell 
lines (Jak1-/-) were compared for differentially expressed genes (A). To compare the 
JAK1-specific effects in a homogeneous population, the isogenic cell lines were 
compared and the resulting heat maps display the top fold change of genes regulated in 
a JAK1-dependent manner (B). Gene set enrichment analysis (GSEA) was performed 






Fig.4.6. Expression of JAK1 target genes confirmed by immunostaining and 
Western blot analysis. The expression of Jak1 demonstrates the loss of exon 2 in the 
knockout cell line samples (KO), highlighted by the blue-shaded area. Example targets 
deregulated by decreased JAK1 expression are Fos and Socs3 (A). Targets identified by 
RNA-Seq results were analyzed by immunostaining in wild type tumors (Jak1+/+) and 
JAK1-deficient mammary tumors (Jak1-/-) and included PDGFRA, OSMR, CD14, BCL3, 
c-FOS, SOCS3, and SOC1, bar, 100 μm (B). Select targets verified by Western blot for 
protein expression, and displayed differential expression between the JAK1 wild type 







Fig.4.7. The re-expression of FOS partially rescues the growth-deficient phenotype 
observed in the JAK1-deficient tumor cells. The expression of FOS in JAK1 wild type 
tumors compared to JAK1-deficient mammary tumors, bar, 100 μm (A). Re-expression 
of FOS in a Jak1 knockout cell line (Jak1-/-) restores levels of FOS at the protein level 
(B). Transplanted FOS-expressing JAK1-deficient cells partially restores growth, and can 
be tracked over the course of the study by bioluminescence, NC, negative control for 
luciferase activity (C). cFOS expression by immunostaining demonstrates positive 
staining in tumors wild-type for JAK1 (Jak1 WT) and JAK1-deficient, but expressing c-
FOS (Jak1 cKO + cFOS), while JAK1-deficient (Jak1 cKO) tissues are negative. Bar, 
100 μm (D).  
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Discussion 
JAK1 plays a critical role in ErbB2-induced mammary cancer progression 
 The deletion of Jak1 in mammary epithelial cells prior to tumor onset did not 
affect the tumor initiation; however, the JAK1-deficient tumors displayed a decrease in 
active STAT3 and STAT1, as well as a decreased propensity to metastasize. The results 
suggest that JAK1 is not crucial for molecular events involved in the initial transformation 
of tumor cells, even though previous work has identified STAT3 in driving transformation 
events [70]. Turkson, et al. demonstrated that STAT3, downstream of Src signaling, 
could produce transformation in NIH3T3 fibroblasts [122]. A similar study, also using 
NIH3T3 cells, showed a role for STAT3 in transformation as well as cell growth 
downstream of tyrosine kinase receptors (TRK) [123]. It should be pointed out, that 
these studies identified a role for STAT3-induced transformation in vitro, and while 
STAT3 may promote transformation in 2D culture, it is either not activated in a JAK1-
dependent manner or necessary in vivo for ErbB2/neu transformation. The Neu proto-
oncogene has been shown to induce tumor formation through intrinsic kinase activity 
along with somatic mutations within the transgene, increasing the transforming 
capabilities [114, 124]. Muthuswamy, et al. identified the Neu transforming capability to 
also include recruitment of c-Src proto-oncogene (Src homology 2) for signal 
transduction events [125]. Due to the unchanged tumor onset in the Jak1-deficient mice, 
it is possible that these transforming events act independently of JAK1. Conversely, 
early events initiate Akt for cell survival and proliferation, which is modulated by JAK2, 
before becoming independent of this Janus kinase for fully transformed and established 
cancer [79], underscoring the importance of signaling events for the various phases of 
tumor progression.  
Addressing tumor progression, our results synergize with ErbB2-driven tumor 
models deficient in STAT3 [126]. Ranger, et al. reported that while there was no 
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difference comparing in vivo tumor initiation of ErbB2 tumors that are Stat3+/+ versus 
Stat3-/-, there was a significant decrease in the metastasis to the lung and concurrent 
reduction in angiogenic response. We observed a similar phenotype of an absence of 
lung metastasis in the transplant of isogenic cell lines and tumor fragments deficient in 
Jak1, both of which displayed a lack of tyrosine-phosphorylated STAT3 in JAK1-deficient 
samples compared to wildtype. The transplant data show that when placed back in vivo, 
there was no indication of reactivation of STAT3, suggesting that another Janus kinase 
family member cannot contribute to STAT3 activation in established disease in the 
absence of JAK1. First, this potentiates the findings from Chapter 3, describing the role 
of JAK1 in normal mammary gland development, where the deletion of the Janus kinase 
1 produced a decrease in activated STATs 1, 3, 6. Also, decreased activation of these 
transcription factors demonstrates that JAK2 could not compensate for their lack of 
activation. In the mammary tumorigensis model, the observation that JAK1 contributes to 
the activation of a similar STAT profile, which also cannot be rescued by another JAK 
family member, supports the critical role for JAK1 in activating specific targets, namely 
STAT3. These results demonstrate that inhibition of this kinase directly may provide 
effective therapy for reducing the activity of STAT3 in established tumor cells, while 
concurrently inhibiting their growth properties in Erbb2-driven human malignancy.  
 
JAK1 contributes to the tumor-initiating cell population 
The striking observation of the impaired growth of JAK1-deficient tumor cells 
upon transplantation indicated a depletion of a tumor-initiating population of cells. The in 
vivo results were replicated in vitro by tumorsphere analysis, as the ErbB2-driven Jak1+/+ 
cells displayed neoplastic characteristics and formed spheres readily in nonadherent 
conditions, whereas Jak1-/- cells had a reduction in sphere formation. The results 
indicate that the ErbB2 model is enriched in tumor-initiating cells, the minor subset of 
 114 
cells that are capable of propagating the bulk of tumors. The ErbB2/Neu tumorgenesis 
drives luminal disease that has been shown to express elevated levels of integrin-beta3 
(CD61) as well as increased amounts of CD49 [118, 127].  While the study by Vaillant, et 
al. described the variation of tumor-initiating cells by CD61 expression in three mammary 
tumor models, MMTV-wnt-1, MMTV-neu, and p53+/-, they concluded that the MMT-neu 
was a homogenous population with little variation in a tumor initiating capability [127]. 
They arrived at this conclusion because they were not able to subdivide additional 
populations of cells from the MMTV-neu tumors, such as Sca-1, CD18, and CD14. Our 
data correlate with their findings, that MMTV-neu tumor cells are comprised of a luminal 
population with high levels of CD61, although the level of CD61 expression is 
dramatically decreased in the JAK1-deficient tumor cells. Interestingly, the expression of 
CD61 correlates with capacity of cells to form spheres, supporting the hypothesis that 
ErbB2 tumors are highly enriched for tumor-initiating cells. This finding implies that JAK1 
may be implicated in the tumor-initiating cell population of established disease. The 
tumor initiating cells have been suggested to be responsible for metastatic disease 
[128], and may explain the reduced propensity of JAK1-deficient cells to metastasize. 
 
Downstream targets of JAK1 signaling contribute to tumor growth 
 We found that the deletion of Jak1 in the Erbb2 murine tumor model establishes 
JAK1 as the critical activator for STAT3 in a tumor cell-intrinsic mechanism. To identify 
downstream targets of JAK1-mediated signaling, we performed whole genome RNA-
Sequencing and GSEA, identifying genes and pathways deregulated in a JAK1-
dependent manner. Among the targets identified were proto-oncogenes, Fos, and 
Map3k8. Interestingly, these genes were also found to be deregulated in a JAK1-
dependent manner during remodeling events of the mammary gland as identified by 
RNA-Seq and verified by immunostaining (Chapter 3, FOS data shown, Map38 data not 
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shown). These data support that JAK1 maintains contribution to similar downstream 
targets from normal development to established disease, pointing to a possible 
conserved mechanism for their activation. We hypothesized whether either of these 
targets would able to reinstate a growth, migratory, or tumorsphere-forming behavior, on 
their own in the absence of JAK1.  
In the first line of rescue experiments, we targeted FOS for re-expression, as the 
proto-oncogene is recognized in cancer progression. FOS family members dimerize with 
Jun to form the Activating Protein-1 transcription factor complex (AP-1), which affects 
target gene expression. In the breast, oncogenic functions of FOS are described to 
contribute to proliferation, loss of polarity, and implicated in aggressive ErbB2-positive 
breast cancer [129, 130]. Re-expression of FOS partially rescued the in vivo growth 
properties of the JAK1-deficient cells, although not to the degree of wild-type JAK1 
tumor cells. Past studies have demonstrated that a knockdown of FOS inhibits MCF7 
breast cancer cell proliferation [131]  and correlated with our paired observations of 
significant Fos deregulation in the JAK1-deficient cells combined reduced growth in vivo. 
However, the replaced expression could not recapitulate a full growth profile compared 
to JAK1 wild-type tumor cells. These results indicate that re-expression of FOS in a 
JAK1-deficient background is not sufficient to drive cancer cell growth. Further studies 
will identify if FOS contributes to migration and the tumor-initiating cell population. Our 
observations indicate that JAK1 contributes to the expression and activation of a network 
of genes that are necessary for driving growth in transformed cells. Further studies that 
replace expression of deregulated targets will depict if there are direct targets of JAK1 














The primary focus of our work explores the molecular regulation of the JAK/STAT 
pathway and its relevance in signal transduction, promoting proliferation and cell 
maintenance. Extensive work has described the role of STAT proteins in development, 
along with their presence and activation in malignancy, much less has been explored in 
relation to their upstream activators, the Janus kinases. Although JAK2 had been highly 
characterized in the developing organ, little was known of the function of JAK1, the other 
predominantly expressed Janus kinase in the mammary epithelium. The mechanism of 
JAK2 is described to mediate PRL and GH signaling, driving the differentiation of the 
alveolar cells through STAT5 [12, 13]. JAK2 was also thought to contribute to the 
involution events, mediating the inflammatory cytokines and activating STAT3 to initiate 
and promote the remodeling of the differentiated gland. However, JAK2 appeared to be 
dispensable for activating STAT3 due to the observation of persistent STAT3 activation 
in Jak2-deficient tumor cells [80]. Due to these observations, we questioned whether 
JAK1 would play a crucial role in the postlactational remodeling events, mediating 
inflammatory cytokine signaling. Furthermore, does JAK1 contribute to inflammatory 
cytokine signaling in mammary tumorigenesis and disease progression? 
We first began studies by developing a conditional knockout of Jak1 to bypass 
embryonic lethality. We confirmed from the previously generated Jak1 conventional 
knockout by Rodig et al. 1998, that JAK1 contributes to the activation of STAT3, and 
additionally, the activation of two other transcription factors expressed in the mammary 
epithelial tissue, STAT1 and STAT6.  Followed by a targeted deletion in the mammary 
gland. We saw no evidence of negative selection against Jak1-deficeint cells during 
development, although importantly, we saw a striking phenotype by a massive delay in 
involution. Further studies confirmed this delay was due to impaired mediation of the 
inflammatory cytokines OSM and LIF, and also the absence in phosphorylation of 
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STAT3. Using RNA-Seq, we identified an array of genes selectively regulated in a JAK1-
dependant fashion, and by ChIP-Seq verified binding targets of STAT3 versus STAT5. 
Two of these targets were BMF and Bcl2l11 (BIM), both proapoptotic proteins that are 
responsible for the initial breakdown of the mammary epithelial cells during involution. 
This was verified first in silico, confirmed at the protein expression level in involution 
samples of wild-type and JAK1-deficient tissue, and demonstrated biologically with 
Bim/Bmf double knockout tissue during involution. These experiments confirmed the 
integral function of JAK1 and its necessity for mediating STAT3 activation in response to 
inflammatory cytokine signaling in mammary gland remodeling.  
Next, we extended our findings to disease initiation and malignant progression. 
There is a plethora of previous publications describing the association of STAT3 and 
aggressive disease [70, 104, 132], and although efforts have been made to target this 
transcription factor directly, success has been limited due to the inherent nature of 
STAT3 existing as a latent factor in the cytoplasm. We targeted the deletion of JAK1 
prior to tumor onset in ErbB2-driven mammary cancer, though we did not observe a 
significant effect on tumor initiation, there was a defined reduction in the occurrence of 
metastatic disease. To compare the effects on tumor progression, we established cell 
lines from tumor mice bearing the Jak1fl/fl alleles and deleted Jak1 via viral-mediated Cre 
recombinase. The cells that were deficient in JAK1 displayed a drastic decrease in 
STAT3 activation. Also, when transplanted into recipient wild-type mice, the tumor cells 
lacking JAK1 had a significant reduction in growth rate and no evidence of metastasis; 
whereas tumor cells harboring wild-type JAK1 grew prolifically and metastasized to the 
lung and in some cases the liver and pancreas. The substantial differences in the growth 
rates indicated an effect on the tumor initiating cell population. Using tumorsphere assay 
in vitro, we observed a striking decrease in the amount and size of tumor-forming cells. 
RNA-Seq analysis identified deregulated genes that mirrored what we observed 
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phenotypically, that the tumor cells had deregulation of adhesion molecules and 
oncogenes (such as c-FOS) in a JAK1-dependant manner. Initial rescue studies showed 
a partial rescue of the delayed growth of tumor cells. Further experiments will 
demonstrate the genes and subsequent proteins necessary for tumor growth 
downstream of JAK1/STAT3 signaling. Interestingly, when human breast cancer cells 
lines which overexpress HER2 are depleted of JAK1, the same transcription factors 
seen in the murine tissue—STAT1, STAT3, and STAT6—demonstrated a lack of 
activation. Functional studies will illustrate whether JAK1 depletion has the same effect 
in human malignancy as observed in our murine studies. If this is the case, then efforts 
made to develop a JAK1-specific inhibitor would be advantageous for targeting active 
STAT3 and preventing metastatic dissemination of breast cancers. The aspect of JAK1 
affecting established cancer is pertinent, as the majority of clinically addressing 
malignancies is for the treatment of established cancers. 
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 The findings from the biological impact of deleting Jak1 in neoplastic tumors were 
surprising and left many questions to be answered. Namely, what are the tumor-initiating 
roles of JAK1 in the primary murine tumor cells, and does the absence of JAK1 in 
human cancer cells impart similar behavior observed in the murine cells? The following 
experiments address JAK1, but also the downstream targets of JAK1 signaling, as well 
as the effect of impacting human health by targeting JAK1 specifically by inhibitors. 
 
Verifying the biological significance of JAK1-dependant targets 
 In continuation of identifying JAK1-dependant target genes responsible for 
growth and proliferation, the target Tpl2 (MAP3K8) will be re-expressed. MAP3K8 has 
been demonstrated to be a potent transforming factor in lung cancers as well as in 
hepatocellular carcinomas [120, 133]. Little is known of its role in mammary tumor 
progression. Results of re-expression in murine mammary tumor cells will verify its 
transformation capabilities and potential to influence growth. Preliminary results indicate 
that MAP3K8 is indeed an oncogene capable of reinstating neoplastic characteristics to 
JAK1-deficient cells (Fig. 6.1). 
 To further verify the expression and JAK/STAT molecular pathways influencing 
expression of these target genes, STAT3 activity will be re-instated in JAK1-deficent 
cells by constitutive mutation of STAT3. The expression of STAT3 and the correlation 
with increased expression of FOS and MAK3K8 would solidify the dependence of 
STAT3 for transcriptional activation, which is regulated in a JAK1-dependant manner. 
Verification by Western blot, qPCR, and immunostaining is expected to confirm 
expression of the targets. 
 
 123 
Addressing the role of JAK1 specifically in ErbB2-driven cancer cells and breast 
cancer tissue 
 In the previous chapter, we described the role of JAK1 contributing to the 
activation of STAT3 along with STAT1 and STAT6 in murine Erbb2-driven tumor cells. 
Extending the role of JAK1 into human disease, we generated a doxycycline-inducible 
shRNA knockdown of human JAK1, and tested the knockdown on MDA-453 breast 
cancer cells, which overexpress the ErbB2 onco-protein. Preliminary results 
demonstrate similar findings, that JAK1 is necessary for the activation of STAT1, STAT3 
and STAT6, in steady-state cell culture conditions (Fig. 6.2A). This contradicts previous 
reports that promote the activation of JAK2 phosphorylating these downstream 
transcription factors [134]. After verifying the knockdown of JAK1 in the human breast 
cancer cell lines, RNA-Seq was performed and verified the knockdown of JAK1 in a Dox-
inducible manner (Fig. 6.2B). In conclusion these initial results are encouraging, as 
perhaps the JAK1-knockdown in human cells may show similar behavior of the murine 
counterparts. Additional future studies will need to address the growth pattern upon 
transplantation and Dox administration, as well as mammosphere assays and migration 
experiments. Additionally, we performed a JAK1-knockdown in the triple-negative cell 
line, MDA 231, and the activation of STAT3 was also decreased, suggesting that JAK1 
may have a role in regulating STAT3 expression across multiple breast cancer subtypes. 
These results are encouraging, as triple negative tumors lack targeted therapy. The 
inhibition of JAK1 could influence the growth and metastatic potential observed in the 
previously described ErbB2 studies (Fig. 6.2C) (Chapter 4). To address the role of JAK1 
in human breast cancer tissue, we are able to collaborate with Dr. Hallgeir Rui at the 
Medical College of Wisconsin for staining human tumor samples. First, ERBB2-driven 
cancer tissue can be stained for the presence of active STAT3 in human breast cancer 
tissue. Protein expression could be analyzed by quantitative imaging for expression of 
 124 
STAT3 in various stages of breast cancer progression, such as pre-malignant tissue, 
pre-treatment biopsies, post-treatment tissue, and recurrent disease. Next, the activation 
of STAT3 would then be compared with the expression of targets identified in the 
previous chapter such as FOS and the previously undescribed oncogene in the 
mammary gland, Tpl2 (MAP3K8).  The validation in conjugation with STAT3 levels would 
support the method of using the expression of these targets as biomarkers for JAK1 
inhibition. 
 
Novel avenues to test JAK1 inhibitors for efficacy both in vitro and in vivo 
We have the tools to directly assess the effects of current and developing 
drugs/compounds targeting either Jak1 or STAT3 activity in cells deficient in Jak1. 
Genetic knockouts biologically simulated the use of an inhibitor, by directly ablating the 
function of a target. Using a novel inhibitor INCB039110, developed by Incyte, targeting 
JAK1 could reveal the specificity of the compound and delineate off-target effects. The 
compound, which has not been validated in an array of normal and transformed cells, 
has been demonstrated to be well tolerated in topical application studies [135]. The 
study could be constructed in a way to test the compound on epithelial cells, 
exemplifying non-tumor samples, tumor cells wild-type for JAK1, and tumor cells 
genetically deficient in Jak1. First describing the effects on non-tumor epithelial cells 
versus immortalized and oncogenically-transformed epithelial cultures, comparing the 
phenotypes and molecular downstream targets of the JAK/STAT pathway such as the 
STATs themselves. This data could then be expanded, comparing the effects of the 
inhibitor on tumor cells lacking JAK1 alongside matching wild-type tumor cells, 
assessing the results for synergy of a JAK inhibitor on wild-type cells versus genetically 
ablated kinase. Concise verification of the effects of drugs in vitro could be analyzed by 
whole genome RNA-Seq, verifying differential gene expression. Building from the initial 
 125 
cell culture analysis, the in vivo application could be demonstrated by transplanting 
MMTV-neu-driven cancer cells wild-type for JAK1, which have shown to engraft, 
proliferate, and produce distant metastasis, or the Jak1-null tumor cells, into the 
mammary gland of Athymic nude mice. This would provide several lines of evidence 
describing the efficacy of the inhibitor. First, it would provide insight to the targeted 
inhibition of JAK1 reproducing the same effects displayed in the previous study 
described in Chapter 4, where a deletion in Jak1 inhibited tumor growth and metastasis 
in transformed cells. This could be done is several stages to address the role of JAK1 
extensively in tumor progression. The transplanted wild-type cells could be allowed 
engraftment and inhibitor could be administered several days post-engraftment, when 
the tumor is 0.5 cm in size, or the tumor could also be allowed to engraft, grow to a 
select size, then biopsied with drug administration shortly after, observing the effects of 
treatment on residual disease concurrently with its effect on metastasis. This 
assessment in drug performance would mimic the clinical administration in human 
disease, where a HER2+ breast cancer may be treated upon diagnosis, during 
advanced disease, or adjuvant/post-operative therapy for refractory disease of the 
primary tumor as well as controlling for present or potential metastatic disease. Moving 
the studies to human breast cancer, HER2+ breast cancer cell lines that have been 
stably infected with an inducible JAK1-knockout by shRNA in a doxycycline-responsive 
manner, can also be used in vitro and in vivo (transplanted into Rag2-/-;Il2rg-/- recipient 
mice), using the same inhibitor treatment strategy. Comparison of the transplanted mice 
with the JAK1-knockdown via Dox alongside the inhibitor treatment would begin with 
tumor measurement by calipers, followed by collection of tumors for molecular analysis. 
Initial studies using Western blot would test for the deregulation of STAT proteins in a 
JAK1-dependent manner. Analysis of previously identified targets of JAK1/STAT3 
 126 
signaling would verify that the same targets are deregulated by the inhibitor similar to a 
JAK1 knockdown or deficiency.  
These future studies will provide valuable insight on the direct contribution of 
JAK1 to breast cancer progression. Understanding the role of JAK1 and its downstream 
effectors in established cancer will demonstrate the significance of clinically targeting 






Fig. 6.1. Expression of MAP3K8 in JAK1-deficient cells demonstrates rescue of 
neoplastic capabilities. Expression of MAP3K8 in cell lacking JAK1 activity 
demonstrates loss of polarity in 2D cell culture (A) (view 10x magnification). Reinstating 
MAP3K8 rescues the phenotype of JAK1-deficient cells (Jak1 KO) by producing 








Fig. 6.2. Expression of JAK1 in human breast cancer cell lines corresponds to the 
activity of STAT3. Using the ErbB2-driven human breast cancer cell line, JAK1 was 
knocked down by inducible shRNA using Doxycyline. Knockdown of JAK1 demonstrates 
reduced activation of STAT1, STAT3, and STAT6, by Western blot, similar to Erbb2-
driven murine disease (A). Initial studies of RNA-Seq depict the reduced expression of 
JAK1 in a Dox-induced manner (B). Preliminary Western blot results of a knockout of 
JAK1 in the triple negative cell line correlates with a decrease in phospho-tyrosine 
STAT3, indicating a broad application of JAK1 regulating STAT3 in breast cancer (C).  
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